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Dengue viruses are mosquito-borne flaviviruses that circulate in nature as four related 
serotypes (DENV1-4). These emerging pathogens are responsible for an estimated 
390 million human infections each year. The outcome of human DENV infection 
ranges from clinically inapparent disease (~75% of infections), to a self-limiting 
febrile illness, to severe disease characterized by hemorrhage and shock. Severe 
clinical manifestations of disease are predominantly associated with secondary 
infections by a heterotypic DENV serotype. The increased risk of severe disease in 
DENV-sensitized populations significantly complicates vaccine development, as a 
vaccine should confer protection against all four DENV serotypes. As the 
development of a neutralizing antibody response is a correlate of protection for 
successful vaccines for several other flaviviruses, eliciting a protective tetravalent 
  
neutralizing antibody response is a major goal of ongoing DENV vaccine 
development efforts. Understanding the neutralizing antibody response to infection 
and vaccination is an important step toward the development and evaluation of safe 
DENV vaccines. While considerable insights have been gained from studies of 
monoclonal antibodies, the individual contributions and dynamics of the repertoire of 
circulating antibody specificities elicited by infection and vaccination are poorly 
understood on a functional and molecular level. We studied human polyclonal 
antibody responses elicited by monovalent DENV1 vaccination and sought to identify 
epitopes recognized by serotype-specific neutralizing antibodies. DENV1 structural 
gene variants were produced and screened for reduced sensitivity to neutralization by 
DENV1 sera but unaltered sensitivity to control antibodies. We identified amino acid 
residues that contribute significantly to type-specific recognition by polyclonal 
DENV1 immune sera. These findings provide an important step towards 
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Chapter 1: Introduction 
 
 
Dengue virus (DENV) is a mosquito-transmitted flavivirus responsible for an estimated 
390 million human infections each year (1). Four related serotypes (DENV1-4) circulate 
in virtually all tropical and sub-tropical regions of the world (2). While DENV infection 
is often subclinical, infected individuals may develop dengue fever (DF), which has 
symptoms of self-limiting febrile illness, myalgia, rash, and retro-orbital pain (3), or more 
severe clinical illness (dengue shock syndrome/dengue hemorrhagic fever) involving 
capillary leakage, thrombocytopenia, and hemorrhage. Severe disease is typically 
associated with secondary infections by a heterologous DENV serotype (4-7). The 
incidence of severe DENV disease is rising globally due to increasing co-circulation of 
multiple DENV serotypes in endemic areas (2, 8). Currently, there are no specific 
treatments or approved vaccines for DENV infection.  
 
DENV infection elicits the production of long-term serum neutralizing antibodies (9). 
The neutralizing antibody response elicited following infection likely contributes to the 
long-lived protection against reinfection that is observed (10). However, immunity 
following primary infection is typically serotype-specific, and thus DENV-experienced 
individuals may be susceptible to secondary infection by a heterologous serotype (11). A 
portion of the immune response after primary infection is cross-reactive against 
heterologous serotypes; however, this cross-reactive response is poorly protective, and 




infections (11, 12). Therefore, a DENV vaccine should provide protection against all four 
serotypes to avoid the incomplete immunity that serves as a risk factor for severe disease. 
Because antibodies against DENV have the potential to mediate protection as well as 
pathogenesis of severe disease, characterizing the polyclonal antibody response to DENV 
infection and vaccination is an important step toward the development and evaluation of 
safe vaccines against DENV.  
 
The principle goal of this dissertation was to identify epitopes involved in the type-
specific neutralizing antibody response elicited by DENV1 vaccination in humans. The 
Laboratory of Infectious Diseases of the National Institutes of Health (NIH) is developing 
a live-attenuated, tetravalent dengue vaccine, and has tested several vaccine candidates 
and formulations in clinical studies (13). Using post-vaccination sera obtained from 
clinical trials of NIH DENV1 and DENV2 monovalent vaccine formulations, we 
developed methods to deconstruct the functional components of a polyclonal antibody 
response. We used a mutagenesis strategy to characterize variants that had a reduced 
sensitivity to neutralization by sera from vaccine recipients. Reporter virus particle (RVP) 
technology was employed for this study, as it streamlines the process of constructing and 
characterizing a large panel of structural gene plasmids. Additionally, RVPs are not 
passaged in cell culture, and thus the genetic stability of a particular mutation does not 
limit its utility in neutralization studies. 
 
In order to study the relevant strains of DENV present in the NIH vaccine candidate, 




DENV1 strain of the tetravalent formulation is derived from the Western Pacific (WP) 
strain (14), and the DENV2 component in this vaccine is derived from the New Guinea C 
(NGC) strain (15). However, initial experiments demonstrated that it was not possible to 
produce RVPs for all DENV strains in our existing method. As outlined in chapter 3, in 
order to study the strains of DENV present in the NIAID vaccine candidate we had to 
decipher why RVPs could not be generated from the required DENV strain, repair the 
cause of the incompatibility with RVP technology, and establish a method for making 
RVPs of the vaccine strains. 
 
Following successful production of DENV RVPs corresponding to the NIH vaccine 
strains, we constructed a large library of DENV1 structural gene variants, which is 
described in Chapter 4. Using sera obtained from volunteers in a clinical trial of the NIH 
DENV1 monovalent vaccine, we screened the DENV1 variants for reduced sensitivity to 
neutralization. Using this strategy, residues on DENV1 that are important for recognition 
by type-specific neutralizing antibodies in polyclonal sera were identified. Variants were 
further characterized by control antibodies to assess whether mutations altered virion 
structure in a manner that would confound our interpretation of the results from the 
polyclonal sera study.  
 
In chapter 5, we investigated polyclonal antibody recognition of heterologous DENV1 
strains by sera from recipients of the DENV1 monovalent vaccine. Since a DENV 
vaccine should induce immunity against the variety of strains in each serotype that 




vaccination against diverse DENV1 strains. We observed that antibodies elicited against 
DENV1 strain WP were capable of neutralizing heterologous strains, though often with 
reduced capacity relative to the strain used in immunization. Studying diverse DENV1 
strains also allowed us to characterize the effect of strain-dependent differences in virion 
structural dynamics on the neutralizing potency of polyclonal sera. Altogether, the 
findings outlined in this dissertation provide insight into the neutralizing antibody 









The genus Flavivirus, of the family Flaviviridae, is a diverse group of positive-stranded 
RNA viruses transmitted to vertebrate hosts principally by mosquito or tick vectors. This 
genus of ~70 viral species includes several viruses of considerable clinical importance, 
including dengue virus (DENV), yellow fever virus (YFV), West Nile virus (WNV), 
Japanese encephalitis virus (JEV), and tick-borne encephalitis virus (TBEV). An 
estimated 390 million humans are infected each year with DENV alone (1). Flaviviruses 
were initially classified using serological studies, which were subsequently confirmed 
and extended via phylogenetic analyses (16, 17). A viral species within the flavivirus 
genus is defined as a group of viruses sharing over 84% nucleotide sequence identity, 
while viruses in a clade share at least 69% nucleotide identity (17). For example, the four 
serotypes of dengue virus (DENV1-4) constitute a clade, with each serotype designated 
as an individual species within the DENV clade (Figure 2.1).  
                                                
1 Adapted in part from: VanBlargan LA, Goo L, Pierson TC. Deconstructing the Antiviral Neutralizing 
Antibody Response: Implications for Vaccine Development and Immunity. Manuscript submitted for 
publication. 





Figure 2.1 Diversity of the surface glycoproteins of flaviviruses. Dendrogram depicting the relatedness 
of selected flavivirus E proteins (scale bar represents 0.1 amino acid substitutions per site). JEV; Japanese 
encephalitis virus; MVEV, Murray Valley encephalitis virus; WNV, West Nile virus; SLEV, Saint Louis 
encephalitis virus; TBEV, tick-borne encephalitis virus; POWV, Powassan virus; YFV, yellow fever virus; 




2.1.2 Viral genome organization and replication 
The flavivirus genome is a single-stranded, positive-sense RNA of ~11 kb in length. The 
genome encodes a single open reading frame (ORF) over 10 kb in length that is flanked 
by 5’ and 3’ untranslated regions. The ORF is translated into a large polyprotein that 
translocates into the membrane of the endoplasmic reticulum (ER) (18). The polyprotein 
is co- and post-translationally cleaved by host and viral proteases into ten proteins, 
including the structural proteins capsid (C), pre-membrane (prM), and envelope (E) that 
are packaged into virions, as well as non-structural proteins NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, and NS5 (Figure 2.2). Viral genome replication occurs in the perinuclear 
region in association with membranes derived from the ER that have undergone virus-
induced ultra-structural reorganization (19). The viral non-structural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5) are present in viral replication complexes, 
along with viral genomic RNA, and likely host factors. Viral genome replication and 
genome packaging are tightly coupled both functionally and spatially (reviewed by (20)). 
Active genome replication has been shown to be a prerequisite for genome-packaging, as 
replication-deficient genomes result in no virus particle production (21). Virus assembly 
occurs at the ER membrane in sites that are distinct from, but in close proximity to sites 





Figure 2.2 Organization of the flavivirus genome. (A) The ~11 kb genome of flaviviruses is organized as 
a single strand of positive-sense RNA that serves as the viral mRNA. The genome has 5’ and 3’ 
untranslated regions (UTR) that flank the single ORF. The ORF contains 10 genes, including the structural 
genes capsid (C), pre-membrane (prM), and envelope (E), as well as seven non-structural (NS) genes. (B) 
The ORF is translated into a polyprotein that spans membranes derived from the ER. Signal sequences 
direct translocation of glycoproteins prM, E, and NS1 into the ER lumen. The polyprotein undergoes co- 




2.1.3 Virus assembly, budding, and maturation 
Assembly of new virions is directed by the prM and E proteins. As nascent virions bud 
into the ER lumen, they acquire a prM- and E-studded lipid envelope that surrounds a 
nucleocapsid composed of C proteins in association with a viral genome (22-24). On 
newly formed virions, one role of prM is to prevent low pH-triggered conformational 
changes in the E proteins that drive fusion of viral and cellular membranes (25). These 
newly formed virions are immature and non-infectious, and must undergo a maturation 
process as they transit the secretory pathway to become mature, infectious virions. Virion 
maturation takes place as immature virions traffic through the secretory pathway, where 
cleavage of the prM protein occurs by cellular furin-like proteases (26-28). This cleavage 
results in a ~75 amino acid M peptide that remains associated with the mature virion, and 
a ~90 amino acid, soluble “pr” portion that disassociates from virus particles upon release 
from cells (29). The function of M on the mature, infectious virion is unknown. 
 
Critically, the flavivirus maturation process is not efficient, resulting in the production of 
a heterogeneous population of virions. Thus, in addition to infectious, fully mature 
virions (no prM) and non-infectious, immature virions (180 uncleaved prM molecules), 
cells produce partially mature viruses that retain structural features of both mature and 
immature virus particles (30). Partially mature virions can be infectious, though the 
extent of prM cleavage required for infectivity is not known (reviewed by (30)). The 
efficiency of virion maturation has the potential to impact virus binding, environmental 
conditions required to trigger membrane fusion, cellular tropism, and sensitivity to 




2.1.4 Flavivirus structure 
Flavivirus virions are small, spherical, enveloped particles roughly 50 nm in diameter that 
are composed of three structural proteins: capsid (C), pre-membrane (prM), and envelope 
(E). The virion maturation process results not only in the loss of the pr peptide, but also 
in a structural reorganization of the E protein. Therefore, immature and mature virions 
have distinct structural organizations. On immature virions, the prM and E glycoproteins 
are incorporated as 60 icosahedrally-arranged heterotrimeric spikes of three prM-E 
dimers (29, 36-38). On mature virions, E proteins exist as a dense herringbone 
arrangement of 90 antiparallel E protein homodimers in T=3 pseudo-icosahedral 
symmetry (Figure 2.3A and 2.3B) (39-41). In this configuration, E proteins lie flat 
against the surface of the viral membrane, in contrast to many other viruses whose 
envelope proteins exist as spikes that project away from the virion surface.  
 
The E protein is the main target of neutralizing antibodies (nAbs) (42). This elongated 
protein is composed of three distinct domains (DI-DIII) connected to the viral membrane 
by a helical stem and two transmembrane domains (Figure 2.3A) (43). A highly 
conserved, hydrophobic fusion loop composed of 13 amino acids is located at the distal 
end of DII (DII-FL). On mature virus particles, the fusion loop is buried in a fold 
composed of DI and DIII of the opposing E protein in the dimer (44). E proteins may 
contain up to two N-linked glycosylation sites (either on DI or DI and DII) (Figure 
2.3C); some strains of WNV are non-glycosylated (45, 46). Neutralizing antibodies have 
been mapped to all three E protein domains, and in many instances, bind epitopes 






Figure 2.3 Structure of the flavivirus E protein. (A) Structure of the ectodomain of the flavivirus E 
protein dimer (PDB: 1OAN) from a side view (top panel) and top view (bottom panel). Domains I, II, and 
III are shown in red, yellow, and blue, respectively. The fusion loop in domain II is shown in green. (B) 
Structure of a mature flavivirus virion (PDB: 4CCT). The E proteins are arranged as 90 antiparallel 
homodimers that densely coat the virion surface. (C) The two possible glycans on the E protein are 





have also been identified, but they have limited neutralization potential and display cell 
type-dependent patterns of activity (S. Mukherjee and T. Pierson, unpublished data) (50, 
59-61). 
 
In addition to virions, subviral particles (SVPs) lacking a nucleocapsid are also produced 
from flavivirus infected cells. SVPs are smaller (~30nm in diameter) than virions and 
have a different symmetry and organization of their E proteins, though SVPs exhibit 
fusogenic properties similar to that of virions (62, 63). In contrast to the 180 E proteins 
packaged into virions, SVPs contain 60 E proteins organized into 30 dimers in T=1 
icosahedral symmetry (62). The differences in the structural organization of virions and 
SVPs results in differential recognition by antibodies, indicating the influence of 
quaternary structure and epitope display on antibody recognition of flaviviruses (64). 
 
2.1.5 Virus entry 
The E proteins orchestrate the entry of flaviviruses into target cells, which occurs through 
receptor-mediated endocytosis, followed by pH-dependent fusion in endosomes (65). 
Cellular factors that mediate virus entry are not completely defined, though attachment 
factors that enhance virion binding to cells have been identified, including C-type lectins 
DC-SIGN and DC-SIGNR, mannose receptor, heparin sulfate, and phosphatidylserine 
receptors of the TIM and TAM protein families (31, 66-70). The role these molecules 
play in the cell biology of virus entry is incompletely understood, and may extend beyond 
simply facilitating virus attachment. To date, cellular proteins required for the low-pH-




capable of fusing directly with synthetic membrane preparations (71, 72). Single particle 
tracking studies suggest virus entry occurs within 17 minutes of stable attachment of the 
virion (73). In vitro studies clearly demonstrate that viral fusion occurs very rapidly 
(within seconds) after exposure to mildly acidic conditions (55, 71, 72).  
 
2.2 Dengue virus 
2.2.1 Diversity 
The DENV serocomplex is divided into four serotypes that share between ~63-77% 
amino acid identity of their E glycoproteins. Despite the genetic differences, the four 
DENV serotypes display similar clinical manifestations and epidemiological features. 
Viruses within a DENV serotype share over 90% amino acid identity. Each serotype is 
further divided into three to five distinct genotypes, with some evidence linking virus 
genotype to disease severity (74, 75).  
 
2.2.2 Distribution 
Together, the dengue viruses are the leading cause of mosquito-borne viral disease in the 
world, with an estimated 390 million infections occurring annually, of which 96 million 
are apparent infections, and 294 are inapparent infections (mild or asymptomatic) (1). 
Due to the widespread distribution of its primary mosquito vector, Aedes aegypti, DENV 
infections occur in countries throughout tropical and subtropical regions in Asia, Africa, 
Australia, and the Americas. Asia bears the highest dengue burden, where around 70% of 




very high rates of seroprevalence. A study in the Ratchaburi Province of Thailand found 
97% of pregnant women had detectable antibodies against DENV (76). Of concern, there 
has been an increase in the frequency and magnitude of DENV epidemics in the past 
several decades, likely due to factors such as increased urbanization, globalization, 
climate change, and vector spread, with predictions that DENV will continue to spread 
(77). There has also been an increase in the co-circulation of serotypes, with many 
DENV-endemic countries having reported detection of more than one, or in some cases 
up to all four DENV serotypes (78). DENV is additionally maintained in a sylvatic cycle 
between Aedes mosquitoes and nonhuman primates, with the potential for spillover into 
the human population (79). 
 
2.2.3 Pathogenesis 
Dengue disease typically manifests as dengue fever (DF), an acute but incapacitating 
febrile illness with symptoms that may include maculopapular rash, headache, myalgia, 
arthralgia, retro-orbital pain, and thrombocytopenia (80). DF is typically self-limiting and 
lasts about one week. However, DENV infection may also result in severe disease such as 
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which are 
characterized by hemorrhagic manifestations and plasma leakage. While rare (~0.5% of 
symptomatic cases), these disease manifestations have the potential to be fatal (1, 80).   
 
The causes of DHF/DSS are not fully understood, but aspects of the host immune 
response have been implicated, particularly during secondary DENV infections. Primary 




protection only against the infecting serotype. Following a brief period of cross-
protection, individuals are susceptible to a secondary infection with a heterologous 
serotype (11). Secondary, heterotypic infections are associated with significantly higher 
rates of severe disease relative to primary infections (4-7). This enhancement of disease 
during secondary infections is likely mediated by the cross-reactive but non-protective 
immune response generated during the primary infection against heterologous serotypes. 
Antibodies have been implicated in DENV pathogenesis through a mechanism called 
antibody-dependent enhancement of disease (ADE), in which non-neutralizing antibodies 
or sub-neutralizing concentrations of antibodies bind the virus and enhance virus uptake 
into cells expressing Fc-gamma receptors (FcγR) such as monocytes, macrophages and 
dendritic cells (81, 82). ADE has been extensively studied in vitro, though the 
mechanisms by which ADE results in severe disease in vivo are not fully understood. 
Increased viremia and altered production of cytokines and other inflammatory mediators 
have been suggested as possible mechanisms (83). The ADE model is supported by 
observations that higher rates of DHF/DSS during primary infection occur in infants born 
to DENV-experienced mothers. Specifically, enhanced disease in infants is frequently 
observed several months after birth, when maternally acquired antibodies have waned to 
levels that are sub-neutralizing and capable of mediating ADE in vitro (79, 84).  
 
Cellular immune responses have also been implicated in severe disease, potentially as a 
result of cross-reactive T cell responses that lead to aberrant cytokine production (85). 
Determinants of disease severity may also include viral-specific factors. For example, 




severe disease during secondary infections has a higher association with the DENV2 
serotype (6, 86, 87). Specific genotypes within serotypes have also been associated with 
more severe disease (88). 
 
2.3 Humoral Immune Response 
A principal component of the humoral immune response is the repertoire of antibody 
molecules secreted by B lymphocytes. Antibodies are Y-shaped glycoproteins composed 
of two identical heavy chain/light chain heterodimers linked by disulfide bonds (reviewed 
by (89)). The arms of antibody molecules (or Fabs) are connected to the remainder of the 
protein by flexible hinges, which diversify the angles with which antibodies may bind 
antigens. The distal end of each arm forms the antigen-binding site of the molecule, 
called the variable (V) region. Both heavy and light chains contain three hypervariable 
loops (called complementarity determining regions, CDR) that come together to form the 
V structural region. The constant (Fc) portion of the antibody is modified by an N-linked 
oligosaccharide that contributes to interactions with molecules and cells of the immune 
system to mediate a range of effector functions (discussed below).  
 
2.3.1 Diversity Of The Humoral Immune Response 
The humoral response is capable of producing an incredibly diverse repertoire of 
antibody molecules with unique antigen binding properties. In part, this diversity is 
encoded directly by the germline. Genes encoding the variable heavy (VH) and light (VL) 




(V), joining (J), and diversity (D) gene segments. Two chromosomes encode the V and J 
gene segments that form the light chain (the κ and λ loci). Full length antibody molecules 
are assembled from these gene segments in developing B lymphocytes by a process 
called V(D)J recombination (reviewed by (90)). This mechanism creates combinatorial 
diversity through the random pairing of VDJ gene segments (at the VH loci) or VJ gene 
segments (at the Vκ or Vλ loci) during somatic gene rearrangement. Additional diversity 
arises during V(D)J recombination because nucleotides are introduced or deleted at the 
junction of segments as they are linked together. The recombined variable region of the 
heavy chain is then joined to µ and δ constant gene segments (to make IgM or IgD 
antibody subclasses, respectively). Random pairing of heavy and light chains results in 
formation of an intact antibody molecule (and B cell receptor (BCR)). The process of 
allelic exclusion ensures each lymphocyte produces only a single antibody molecule 
(reviewed in (91)).  
 
2.3.2 Germinal center formation and affinity maturation 
The antibody repertoire produced by B-lymphocytes is refined and diversified further 
upon exposure to antigen. With appropriate T cell help, B cell recognition of an antigen 
results in cellular activation, extensive proliferation, and potentially Ig class switching, 
during which the Fc portion of the antibody gene can be exchanged for another with 
different functional properties. Antigen-primed B cells can develop into short-lived 
plasma cells (PCs), which are terminally differentiated cells characterized by high 
antibody secretion and low BCR expression. PCs and their proliferating precursors, 




2.4). Antigen-primed B cells can also participate in the formation of germinal centers 
(GCs), along with follicular helper T cells (TFH) and follicular dendritic cells (FDC). GC 
reactions result in the production of long-lived plasma cells and memory B cells 
(discussed further below) (92), although memory B cells may also arise from GC-
independent mechanisms (93). 
 
In GCs, B cells refine the antibody response via the process of affinity maturation. 
Affinity maturation occurs through iterative rounds of somatic hypermutation, during 
which point mutations are introduced into the antibody V regions, followed by TFH cell-
based selection of clones with the highest antibody affinity. One study estimated that the 
average number of mutations in the VH region of IgG among memory B cells and 
germinal center cells was 14, with 88% of the sequenced VH genes encoding between 
three and 29 mutations (94). GCs are sites of competition among B cell clones for T cell 
help. After multiple rounds of affinity-based selection, GCs may undergo 
“monoclonalization”, with one high-affinity B cell clone beginning to dominate any 
given mature GC (reviewed by (95)). In GCs, TFH cells also signal B cells to initiate class 
switching (96-98). 
 
2.3.3 Effector Functions Of Antibodies 
While the Fab region of an antibody defines its specificity, the invariant Fc portion of the 
heavy chain determines its effector function. The antibody class switching mechanism of 
B cells has the potential to create antibodies of similar specificity capable of orchestrating 




Figure 2.4 Sources of antibodies. Upon naïve B cell recognition of an antigen and activation by a cognate 
T cell, activated B cells undergo extensive proliferation. Activated B cells can then follow one of several 
paths: (i) they may terminally differentiate into short-lived plasma cells (PCs) which have low surface Ig 
levels and high Ig secretion rates; (ii) they may differentiate into memory B cells (MBCs) which retain 
BCR expression but do not constitutively secrete antibody; (iii) they can participate in the formation of 
germinal centers (GCs), along with follicular helper T (TFH) cells and follicular dendritic cells. In GCs, B 
cells undergo rapid proliferation, further diversification of their antibody gene through somatic 
hypermutation, and class-switch recombination (CSR) during which the Fc region of the Ig gene may be 
exchanged for another to modulate antibody effector function. Selected GC B cells receive signals to 
differentiate into PCs or MBCs; other GC B cells undergo apoptosis. PCs may be short-lived and remain in 
the lymphoid organs, or become long-lived plasma cells (LLPCs) and migrate to the bone marrow, where 
they will continue to secrete antibody independent of the presence of antigen. LLPCs are most likely 
responsible for the long-lived, pathogen-specific antibody titers in serum that can last years or decades 
following infection or vaccination. Distinct from LLPCs, MBCs are long-lived cells that remain in 
circulation and peripheral lymphoid tissue. Through expression of their BCR, they can be re-activated by 
antigen. Upon re-stimulation, they may set up germinal centers, undergo further somatic hypermutation and 









receptors (FcR) on immune effector cells or soluble immune molecules such as those in 
the complement system (89). The strength of these interactions varies among antibody 
class and can be influenced by the particular carbohydrate modification on the antibody 
molecule (99, 100). All IgG subclasses encode an N-linked glycosylation site at residue 
297 of the heavy chain. While the position of the glycosylation site is conserved, the 
composition and structure of the oligosaccharide added to the antibody is influenced by 
the host immune activation state (101, 102). This provides the immune system with an 
ability to tune antibody effector function beyond class switch recombination during the 
course of the immune response. For example, the IgG repertoire of HIV-infected 
individuals is modified by sugars with an agalactosylated, pro-inflammatory glycan 
profile as compared to uninfected individuals; this is particularly pronounced in elite 
controllers of HIV (103). Of interest, changes in the carbohydrate profiles of HIV-1 
reactive and non-reactive antibodies differed within individuals. This skewing towards 
agalactosylated antibodies in infected individuals and elite controllers correlated with 
increased antibody-dependent cellular viral inhibition (ADCVI) activity in vitro.  
 
The antibody heavy chain orchestrates antibody effector functions including antibody-
dependent cellular cytotoxicity (ADCC), opsonization, mast cell activation, and 
complement activation. Thus, non-neutralizing antibodies elicited by immunization or 
infection may offer protection from viral infections through effector functions mediated 
by the Fc region. Studies in murine models of both WNV and HIV-1 infection have 
demonstrated the importance of the Fc effector functions of antibodies in mediating 




neutralizing ability can mediate in vivo protection in mice, but eliminating IgG binding to 
complement component C1q and Fcγ receptors via removal of the N-linked glycan at 
N297 eliminated their protective capacity (104). Conversely, the inability of strongly 
neutralizing mAbs with mutations at N297 to interact with Fcγ-receptors may be 
exploited for the development of DENV therapeutics, as these non-glycosylated nAbs do 
not support (and may competitively inhibit) the antibody dependent enhancement 
processes thought to contribute to severe disease outcomes (108, 109). 
 
2.3.4 Where Do Antiviral Antibodies Come From? 
Long-term humoral immunity results from at least two distinct cell populations (Figure 
2.4). Long-lived plasma cells (LLPCs) constitutively secrete antibody independent of the 
presence of antigen, and are most likely responsible for the long-lived, pathogen-specific 
antibody titers in serum that can last years or decades following infection or vaccination 
(110, 111). LLPCs reside predominantly in the bone marrow and are terminally 
differentiated. They do not possess antigen receptors and are not reactivated upon antigen 
re-exposure. In contrast, memory B cells (MBCs) remain in circulation and peripheral 
lymphoid tissue where they may re-encounter antigen (112). MBCs express BCR on their 
surface, but do not constitutively secrete antibody. Upon re-stimulation by antigen, 
MBCs may differentiate into antibody-secreting plasma cells, and may form germinal 
centers to undergo further affinity maturation and class switching (113). MBCs are 
responsible for the anamnestic antibody response that occurs upon secondary exposure to 
an antigen, responding more rapidly and in greater magnitude to antigenic stimulation 





LLPCs and MBCs differ with respect to the extent of the affinity maturation of the 
antibodies they express (114). Only B cells capable of producing antibodies with high 
affinity for the antigen are selected for LLPC formation and persistent antibody 
production, whereas B cells that produce antibodies with lower affinity for antigen may 
survive as MBCs (114, 115). Antibodies from these two compartments may differentially 
contribute to protection from infection. A study by Purtha et al. (116) demonstrated that, 
following infection of mice with WNV, antibodies from MBCs were able to recognize 
not only the infecting strain of WNV but also a variant encoding a mutation in a known 
neutralizing antibody epitope. In contrast, the LLPC antibody response was specific for 
the infecting strain. Thus, while LLPC-derived antibody was of higher affinity and 
capable of conferring immediate protection against homotypic viral reinfection, the MBC 
compartment may be critical for the recognition of a genetically diverse challenge.  
 
2.4 Antibody-mediated neutralization 
Antibody-mediated neutralization is defined as direct inhibition of viral infectivity that 
occurs as a result of antibody binding to the virus particle. How antibodies block 
infection has been studied intensely for decades (reviewed by (117, 118)). Because nAbs 
have great potential as antiviral therapeutics, and often correlate with protection 
following vaccination (119), structural and molecular insights into mechanisms of 
neutralization have considerable translational value. Recent technical advances that 
enable the isolation and study of human monoclonal antibodies have not only accelerated 




reference to guide reductionist mechanistic studies towards antibodies with the most 
relevant specificities in vivo (120, 121). 
 
2.4.1 Neutralization By The Numbers 
How many antibodies are required to neutralize a virus? The stoichiometry of antibody-
mediated neutralization has been intensely debated (reviewed in (122, 123)). A “single 
hit” model suggests that one antibody molecule binding to a virus particle in the right 
location is sufficient to inactivate the virion. This hypothesis has been supported largely 
by kinetic arguments in studies of poliovirus, Western equine encephalitis virus, and 
influenza (124, 125). However, limitations of these kinetics arguments have been 
reviewed (118). An alternative “multiple-hit” model proposes that neutralization of an 
individual virus particle requires engagement by numerous antibody molecules (122). An 
interesting extension of this model suggested that the number of antibodies necessary for 
neutralization was a reflection of the size of the virion because of a requirement to fully 
occlude its surface (reviewed by (123)). Estimates of the stoichiometry of neutralization 
have been determined for multiple viruses, including phage MS2 (126), poliovirus (127-
129), WNV (130), papillomavirus (131), influenza virus A (125), and rabies virus (132, 
133). While in many cases the neutralization threshold for structurally distinct groups of 
viruses does indeed correlate positively with virion size in agreement with the “coating 
theory” (123), factors that determine the number of antibodies required for neutralization 
are not well understood. For example, the small number of functional trimers on the HIV-
1 surface allows for neutralization with a stoichiometry much lower than predicted for a 




that bind an epitope on the lateral ridge of DIII suggest that the binding of 30 mAbs to the 
virion is required for neutralization (Figure 2.5, inset) (130, 136). How the stoichiometric 
requirements for neutralization of flaviviruses differ among epitopes or neutralization 
mechanisms (see section below) is unknown (137). In support of this caveat, the number 
of antibodies required to neutralize infection via different mechanisms has been 
suggested to differ (58, 138). At least two factors have been shown to govern how many 
antibodies may bind the virion at any given concentration of antibody (reviewed by 
(137)). Antibody affinity determines the fraction of viral epitopes bound in the presence 
of a particular mAb concentration. More critically, the accessibility of epitopes on the 
intact infectious virion provides the “denominator” for this relationship: epitope 
accessibility ultimately governs the number of antibodies capable of binding at saturation. 
Not all epitopes are equally accessible for binding (Figure 2.5, inset), and many factors 
with the potential to impact epitope accessibility have been described (for flaviviruses, 
see (137)). Factors that reduce epitope accessibility may make viruses less sensitive to 
neutralization, and thus have the potential to contribute to immune evasion, as detailed 
below. Further studies to correlate epitope location, neutralization, and the occupancy 
requirements for neutralization are warranted.   
 
2.4.2 Mechanisms Of Neutralization 
Antibodies have the ability to block viral infection at any number of steps in the process 
of viral entry (reviewed by (118)). These include viral attachment to the cell surface, viral 
interactions with receptors or co-receptors, fusion with host membrane (for enveloped 




Figure 2.5 Flavivirus entry and mechanisms of antibody-mediated neutralization. (A) Flavivirus entry 
occurs following viral interaction with attachment factors such as C-type lections DC-SIGN and DC-
SIGNR, mannose receptor, heparin sulfate, and phosphatidylserine receptors of the TIM and TAM protein 
families. (B) Following virus attachment, flaviviruses undergo clathrin-mediated endocytosis. (C) They can 
then enter the cytoplasm by pH-dependent fusion in the endosome. Antibody-mediated neutralization of 
flaviviruses may be achieved by inhibiting virus infectivity at a number of viral entry steps such as (i) 
preventing virus attachment to the cell surface, (ii) promoting virus detachment from cells, and (iii) 
inhibiting viral fusion with endosomal membranes. Inset: Neutralization occurs when antibodies bind 
flaviviruses with a stoichiometry that exceeds a particular threshold (130). Antibody-dependent 
enhancement of infection (ADE) can occur if the number of antibodies bound to the virion does not reach 
the stoichiometric threshold for neutralization. The number of antibodies bound per virion is modulated by 
antibody affinity as well as by epitope accessibility. Therefore, antibodies that bind cryptic epitopes that are 
poorly accessible for antibody recognition may not be able to achieve a stoichiometry sufficient to exceed 
the threshold requirements for neutralization, despite high affinity for the epitope. In contrast, antibodies 









genome uncoating (Figure 2.5). Blocking cell surface attachment or receptor engagement 
through steric hindrance may be a common mechanism, and has been suggested to 
explain the activity of DENV-immune sera (139). However, many antibodies have been 
shown to be capable of blocking infection at a post-attachment step (48, 56, 140-143). 
These nAbs may inhibit conformational changes of a viral protein required to mediate 
virus entry. For example, the WNV-specific mAb E16 has been shown structurally to trap 
E proteins in a radially extended intermediate at low pH (144). Like E16, the mAb 
CR4354 inhibits WNV at a post-attachment step and can inhibit viral fusion with 
synthetic liposomes (56, 145). The structure of CR4354 Fab bound to WNV revealed a 
discontinuous epitope that spanned neighboring E proteins, suggesting this mAb and 
others that bind complex quaternary epitopes might block fusion by crosslinking E 
proteins on the virion (145). While the multiple-hit hypothesis assumes neutralization is a 
reversible process (146), in some cases, antibody binding results in an irreversible change 
in virion infectivity that persists upon reversal of binding. Anti-HIV mAbs that bind the 
membrane-proximal external region (MPER) on gp41 induce shedding of viral 
glycoprotein gp120 from the virion, which renders virions non-infectious even when 
antibody binding is reversed (147).  
 
While Fab fragments of neutralizing antibodies can block infection (117), the Fc region 
of antibodies is also likely important for neutralization. While the surface area buried by 
an epitope/paratope interaction is relatively small, generally less than 900 Å2 (148), the 
intact antibody molecule has the potential to occupy a very large area due to its structural 




entire molecule, which has the potential to not only influence the number of antibody 
molecules docked on the virion (relative to Fab fragments), but also interfere with many 
processes that occur during viral entry (64, 149). For example, the orientation of the Fc 
region of virus-bound Abs has been hypothesized to control the number of WNV DIII-
reactive mAb E33 molecules docked to viruses of different maturation states (150). Thus 
the large size of the antibody molecule has the potential to influence the accessibility of 
surrounding epitopes and thereby impact conditions that support antibody-mediated 
neutralization.  
 
2.5 Viral Evasion Of Antibody-Mediated Neutralization 
2.5.1 Sequence Variation And Antigenic Diversity 
Viral genomes mutate at a relatively rapid rate, allowing the selection of mutations within 
epitopes recognized by antibodies (151, 152). Viruses that can tolerate a large number of 
mutations in their structural proteins, such as HIV, hepatitis C virus (HCV), influenza 
virus, and noroviruses allow for rapid and substantial antigenic drift in the presence of 
immune pressure (121, 153-156). This is evident in the yearly requirement for 
reformulation of the seasonal influenza vaccine, as influenza viruses are extremely adept 
at acquiring mutations that aid in antibody-escape (157, 158). For viruses that cause 
chronic infections, intra-host generation of antigenic diversity is observed over time as 
new viral variants emerge to escape the nAbs generated early in the immune response. As 
the antibody response evolves to recognize poorly neutralized variants, new viral variants 
emerge to escape those antibodies. This iterative selection of neutralization-escape 




rapid antigenic evolution is not apparent for all viruses, even among RNA viruses with 
error-prone RNA polymerases. The monovalent YFV vaccine 17D has been in use since 
the 1950s. Due to a lack of significant antigenic drift, there has not been a need to 
reformulate the YFV vaccine, even after 60+ years of use (162). Many factors could limit 
the impact of the humoral immune response on shaping viral evolution, such as 
differences in viral transmission, replication, or pathogenesis, and the existence of viral 
reservoirs. 
 
2.5.2 Conformational Masking Of Conserved Regions 
Conserved structural features may play important functions in the viral life cycle and may 
be less tolerant to sequence variation and thus represent a site of vulnerability to 
antibodies. Many viruses have therefore evolved mechanisms to conceal conserved 
regions of their structural proteins. For example, the “canyon hypothesis” speculates that 
the receptor binding domain (RBD) of some picornaviruses is buried in a canyon on the 
surface of the viral capsid in order to protect it from immune recognition (163), although 
this strategy is imperfect (164). Likewise, the HIV-1 gp120 RBDs are positioned in 
recessed pockets of the envelope spike that are not accessible for recognition by most 
antibodies (165, 166). The DII-FL of flaviviruses is critical for mediating fusion during 
viral entry, is highly conserved among distantly related flaviviruses, and frequently 
targeted by the antibody response (discussed below) (167-169). However, antibodies with 
this specificity are typically characterized by limited neutralizing activity because of the 




of the opposing E protein on the structure of the mature virion (54, 170). Numerous other 
examples of cryptic flavivirus epitopes have been reported (138, 171-173). 
 
2.5.3 Regulation of epitope accessibility by flaviviruses 
At least two factors have the potential to modulate the accessibility of epitopes on 
flaviviruses. While steric constraints limit antibody accessibility on the mature virion, 
inefficient maturation of flaviviruses results in the release of partially mature virions on 
which epitope accessibility may differ (32, 33, 35, 170). Decreasing the efficiency of 
virion maturation results in an increase in neutralization sensitivity for many classes of 
antibodies (32). The conformational dynamics of E proteins incorporated into the virion 
also modulates epitope accessibility. Viral “breathing” has been shown in several systems 
to impact neutralization sensitivity (138, 174-177). Antibodies have the potential to trap 
transiently exposed structures as they appear in the ensemble of structures sampled by 
flaviviruses at steady state. Recent studies have demonstrated that the reversible exposure 
of cryptic epitopes by WNV and DENV contribute to time-dependent patterns of 
neutralization (138, 178). Similar observations have been made with antibodies to 
internal components of the capsid of some picornaviruses (174). Conformational 
dynamics of Env may also impact epitope exposure and neutralization sensitivity of HIV-
1. When the conformational dynamics of two HIV strains were compared by single-
molecule fluorescence resonance energy transfer (smFRET), the laboratory-adapted, 
neutralization-sensitive strain demonstrated increased dynamics and transitioned more 
frequently between closed and open conformational states compared to the clinically 





2.5.4 Low Density Of Surface Glycoproteins 
As mentioned, the dense arrangement of flavivirus E proteins may impose steric 
constrains on antibody epitope accessibility. However, viruses may also evade 
neutralization by decreasing the number of structural proteins displayed on their surface. 
A reduction in the number of surface glycoproteins that can be targeted by nAbs may 
prevent antibody engagement from exceeding the stoichiometric threshold required for 
neutralization. Human cytomegalovirus (HCMV) has been shown to reduce incorporation 
of the surface glycoprotein gH under selective pressure by antibody in vitro, resulting in a 
resistance to neutralization by gH-specific mAbs (180). A relatively low density of 
structural proteins on the surface of virions may also prevent bivalent engagement of the 
virus particle by antibody, which in turn limits antibody avidity. This has been suggested 
to limit the neutralizing activity of some HIV-reactive mAbs (reviewed by (181)). 
Biochemical and structural studies have estimated that the average HIV virion has a small 
number of Env spikes on its surface (<15) (182-184). Comparisons of the neutralization 
potency of IgG and Fab fragments of anti-HIV antibodies revealed similar potencies, 
suggesting bivalent recognition is uncommon (181). However, elegant studies by 
Björkman and colleagues with engineered antibody-based molecules capable of intra-
spike bivalent binding demonstrate greatly increased neutralization potencies for 
antibodies with certain epitope specificities (185). While the densely packed, pseudo-
icosahedral arrangement of E proteins on flavivirus virions may allow bivalent 




specific mAb E106, has been characterized to date that requires bivalent binding for its 
neutralizing activity (186).  
 
2.5.5 Glycan Shields 
Although flavivirus E proteins contain only a limited number of glycans (1-2), many viral 
structural proteins contain multiple glycosylation sites, which can mediate immune 
evasion (reviewed by (187)). The presence of N- and O-linked glycans may lower the 
immunogenicity of particular regions of viral glycoproteins, as carbohydrate structures on 
virions may be recognized as “self” by the immune system (166). Several viruses, 
including HIV-1, Ebola virus, and HCV, utilize a ‘glycan shield’ to avoid antibody 
recognition (159, 188). For example, the HCV envelope glycoproteins E1 and E2 
together have up to 16 N-linked glycosylation sites, most of which are highly conserved. 
Several of the glycans on the E2 glycoprotein have been shown to influence the 
susceptibility of HCV virions to neutralization (188). Additionally, changes in the 
composition of a glycan shield provide a mechanism to rapidly evolve in response to 
immune pressure. Alterations in the number, placement, and type of glycans on HIV-1 
and simian immunodeficiency virus gp120 occur in order to mask epitopes recognized by 
nAbs (159, 189, 190). How the E protein glycosylation status of flaviviruses affects 
antibody recognition is not well understood, though antibodies that make contacts with 





2.6 The Humoral Immune Response to DENV 
Several lines of evidence suggest the important role that the humoral response plays in 
protection against DENV. Antibody responses serve as correlates of protection for 
vaccines against related flaviviruses, including yellow fever virus (YFV), Japanese 
encephalitis virus (JEV), and tick-borne encephalitis virus (TBEV) (192-195). Cohort 
studies in DENV-endemic areas have observed that pre-existing homotypic DENV nAb 
titers correlate with protection from DENV infection (196). Additionally, in animal 
models for several flaviviruses including for DENV, passive transfer of mAbs can 
mediate protection from infection (47, 48, 142, 197-199). However, antibodies also have 
the potential to be pathogenic during DENV infection through ADE, complicating our 
understanding of their role in mediating protection, and our ability to exploit them for the 
development of anti-DENV vaccines and therapeutics.  
 
In addition to the humoral immune response, the cellular immune response may also 
contribute to protection from DENV infection, though its role is not completely 
understood. In mouse models, immunization with DENV-derived CD4+ or CD8+ T cell 
epitopes enhances host control of infection following challenge with DENV (200, 201). T 
cell depletion and adoptive transfer experiments have further suggested a role for T cells 
in contributing to protection from DENV infection in mice (201-204). In humans, HLA 
alleles have ben associated with DENV disease severity (205-211). One comprehensive 
study of CD8+ T cell responses in DENV-endemic population additionally revealed an 
association between HLA alleles and the magnitude of the T cell response. Certain HLA 




increased risk of severe disease, while other alleles correlated with strong, multi-
functional T cell responses and protection from severe disease (212). This study further 
demonstrated that the majority of the CD8+ T cell response is directed against epitopes on 
nonstructural proteins 3, 4B, and 5, suggesting that the inclusion of these proteins may be 
advantageous for a DENV vaccine.  
 
2.6.1 The Antibody Response to Primary DENV Infection 
Following primary DENV infection, anti-DENV IgM appears within three to eight days 
of the onset of illness (213). The class-switched IgG subsequently appears 10-15 days 
after the onset of symptoms, and is predominantly made up of IgG1 and IgG3. The IgM 
response is short-lived and declines to undetectable levels in most patients within 60 days 
following infection (214). In contrast, the IgG response is long-lived, with IgG detectable 
by both ELISA and plaque reduction neutralization test (PRNT) more than 60 years after 
infection (9). 
 
The antibody response elicited by a primary DENV infection typically exhibits cross-
reactivity against heterologous serotypes, but potent neutralization only against the 
homologous serotype (57). The individual antibodies that constitute a polyclonal 
antibody response to DENV vary with respect to their specificity, breadth, and potency 
(47-49, 215, 216). While the potently neutralizing fraction of the antibody response 
following primary infection or vaccination is predominantly specific for the infection 
serotype (type-specific), the majority of antibodies isolated from DENV-infected humans 




response is thought to offer long-lasting protection against homotypic reinfection with the 
homologous serotype, while the cross-reactive response appears to induce a short-lived 
period of cross-protection, but likely wanes below protective levels, leaving DENV-
experienced individuals susceptible to secondary, heterotypic infections with the 
remaining three serotypes (11). As the cross-reactive antibody response wanes below 
protective levels, it may contribute to DENV pathogenesis during secondary, heterotypic 
infections through the mechanism of ADE.  
 
2.6.2 The Antibody Response to Secondary DENV Infection 
During secondary DENV infections, there is a rapid and potent proliferation of cross-
reactive plasmablasts that predominantly secrete IgG (217). The antibody response 
following secondary DENV infections is characterized by increased cross-reactivity to 
heterologous serotypes relative to primary infections (218, 219). The cross-reactive 
response elicited by secondary heterotypic infections appears to offer protection against 
the remaining two serotypes, as the likelihood of developing DF during a post-secondary 
infection (3° or 4°) is significantly reduced relative to primary and secondary infections 
(220). Hospitalization for 3° or 4° DENV infections is rare. However, post-secondary 
cases that do result in clinically apparent disease may be just as likely to lead to DHF as 





2.6.3 The Antibody Response to DENV Vaccination 
Though no DENV vaccine is currently licensed, numerous candidates have advanced to 
testing in clinical trials, including several live-attenuated vaccines, a recombinant E 
protein vaccine, a purified inactivated virus vaccine, and a DNA vaccine (reviewed by 
(222)). The most clinically advanced vaccine candidate is a live-attenuated, tetravalent 
vaccine (CYD-TDV) from Sanofi Pasteur that has been tested for efficacy in a phase IIb 
trial and in two phase III trials (223-225). CYD-TDV is a chimeric vaccine that utilizes 
the YFV vaccine strain 17D as a backbone, but incorporates structural genes (C, prM, 
and E) derived from each of the four DENV serotypes. CYD-TDV displayed modest 
protective efficacy in phase III trials, with overall efficacies of 61% and 67% in the Latin 
American and Asian trials, respectively. Efficacy studies were performed in school 
children in DENV-endemic areas in Asia and Latin America that had high seropositivity 
rates (~70-80%) before the administration of the vaccine. While efficacy was high (74-
84%) in vaccinees that were seropositive before being vaccinated due to prior exposure to 
DENV, vaccine efficacy was low (35-42%) in individuals that were DENV-naïve before 
vaccination, demonstrating the vaccine’s limited ability to prime a novel immune 
response (223, 225). Interestingly, despite the fact that CYD-TDV induced balanced 
neutralizing antibodies against all four serotypes in vitro, vaccine efficacy was not 
uniform among the serotypes. Efficacy against DENV3 and DENV4 ranged from 74-
78%, efficacy against DENV1 was 50%, and low efficacy was observed for DENV2 (35-





2.7 Remaining questions 
The observation that CYD-TDV elicited a neutralizing antibody response yet was not 
protective against DENV2 infection highlights the need for a better understanding of the 
immune response to DENV. Notably, the neutralization titers against DENV2 were 
comparable to those against the other serotypes (223). What type of immune response is 
protective against DENV and how can we measure it? Is the immune response that 
mediates protection different for DENV2 than for other serotypes? Are neutralizing 
antibodies a correlate of protection for DENV? Is the current plaque-reduction 
neutralization test (PRNT) a valid test for assessing the antibody response? Is there a 
qualitative or functional difference between antibodies elicited following natural 
infection versus those elicited following tetravalent vaccination? Notably, CYD-TDV 
contains only structural genes from DENV; the nonstructural genes are from the YFV 
backbone. Are the non-structural proteins important for immune recognition?  
 
The increased risk of severe disease in DENV-sensitized populations significantly 
complicates vaccine development. In order to avoid the potential for vaccine-mediated 
enhanced disease, a vaccine must confer protection against all four DENV serotypes. 
Therefore, it is crucial to understand the humoral immune response to DENV not only in 
the context of individual and sequential infections, but also in the context of multivalent 
vaccination. While primary infection with one serotype induces a type-specific response, 
it is not known whether primary exposure to all four serotypes simultaneously, as during 
tetravalent vaccination, skews the immune response toward the production of antibodies 




simultaneously generated. In this dissertation, we sought to gain insight into the humoral 





Chapter 3: Context-dependent cleavage of the capsid protein by the 





Molecular mechanisms that define the specificity of flavivirus RNA encapsulation are 
poorly understood. Virions composed of the structural proteins of one flavivirus and the 
genomic RNA of a heterologous strain can be assembled and have been developed as 
live-attenuated vaccine candidates for several flaviviruses. In this study, we discovered 
that not all combinations of flavivirus components are possible. While a West Nile virus 
(WNV) sub-genomic RNA could readily be packaged by structural proteins of the 
DENV2 strain 16681, production of infectious virions with DENV2 strain NGC 
structural proteins was not possible, despite the very high amino acid identity between 
these viruses. Mutagenesis studies identified a single residue (position 101) of the DENV 
capsid (C) protein as the determinant for heterologous virus production. C101 is located 
at the P1’ position of the NS2B/3 protease cleavage site at the carboxy-terminus of the C 
protein. WNV NS2B/3 cleavage of the DENV structural polyprotein was possible when a 
threonine (Thr101, 16681) but not a serine (Ser101, NGC) occupied the P1’ position, a 
finding not predicted by in vitro protease specificity studies. Critically, both serine and 
threonine were tolerated at the P1’ position of WNV capsid. More extensive mutagenesis 
revealed the importance of flanking residues within the polyprotein in defining the 
                                                
2 Adapted from reference 226. VanBlargan LA, Davis KA, Dowd KA, Akey DL, Smith JL, Pierson TC. 
2015. Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the 




cleavage specificity of the WNV protease. A more detailed understanding of the context-
dependence of viral protease specificity may aid the development of new protease 
inhibitors and provide insight into associated patterns of drug resistance.  
 
3.2 Introduction 
West Nile virus (WNV) and the four serotypes of dengue virus (DENV1-4) are mosquito-
borne viruses of the Flavivirus genus that significantly impact public health (227, 228). 
Despite a clear need, neither vaccines nor therapeutics for WNV or DENV have been 
licensed for use in humans. The flavivirus genome is an ~11 kb, single-stranded, positive-
sense RNA that encodes a single open reading frame flanked by 5’ and 3’ untranslated 
regions. The viral genome is translated on endoplasmic reticulum (ER)-derived 
membranes into a single polyprotein that undergoes co- and post-translational cleavage 
by the viral protease NS2B/3 and host proteases into ten functionally distinct proteins, 
including the structural proteins capsid (C), premembrane (prM), and envelope (E) that 
form the virus particle. During assembly, membrane-anchored prM and E glycoproteins 
are incorporated into virions as they bud into the ER lumen. The C protein associates 
with the viral genome in the cytoplasm to form an unstructured nucleocapsid that is 
incorporated into the budding particle via unknown mechanisms (40). The carboxy-
terminus (C-terminus) of the C protein includes a signal sequence, flanked by protease 
cleavage sites, that directs the translocation of prM into the ER lumen and tethers C to the 
cytosolic face of the ER membrane. Cleavage at both sites is essential for virion 
morphogenesis and occurs in a sequential manner (229-231). NS2B/3 first cleaves the C 




exposure of the cleavage site on the luminal side of the ER membrane that is recognized 
by a cellular signalase. Signalase cleavage remains inefficient until NS2B/3-mediated 
cleavage has occurred, and uncoupling the coordinated processing of the C protein 
decreases the nucleocapsid incorporation into virions (232, 233). 
 
The flavivirus protease is a complex of the viral proteins NS2B and NS3, the latter of 
which contains the proteolytic domain (234-236). NS2B is an essential co-factor that aids 
in NS3 folding and substrate recognition and contains a hydrophobic domain that tethers 
the protease to the ER membrane (237, 238). NS2B/3 cleaves at least five positions 
within the membrane-associated viral polyprotein in addition to the C protein (234, 239, 
240). Due to its essential role in flavivirus replication, the proteolytic activity of NS2B/3 
is an attractive target for the development of antiviral drugs (reviewed by (241)). The 
feasibility of designing flavivirus protease inhibitors is suggested by the successful 
development of protease inhibitors for hepatitis C virus (HCV), a related hepacivirus in 
the Flaviviridae family. Numerous HCV protease inhibitors have been approved for 
treatment of HCV by the FDA (reviewed in (242)). However, while compounds with 
inhibitory activity against recombinant flavivirus proteases with activity in cell culture 
have been described (241, 243-248), no compounds with in vivo activity have been 
described. 
 
The design of peptidic or peptidomimetic inhibitors that bind the active site of viral 
proteases is informed by a detailed understanding of the specificity of substrate 




dibasic motif at the P1 and P2 positions (upstream of the cleavage site), and a small side 
chain amino acid (G, A, S, or T) at the P1’ position (downstream of the cleavage site), 
according to Schechter and Berger nomenclature (249). This is reflected in the results of 
substrate specificity profiling studies performed with recombinant proteases of several 
flaviviruses, including WNV and DENV (250-258). However, while considerable insight 
has been gained from studies with recombinant proteases or model substrates, it is not 
known how conditions used in these assays influence cleavage specificity, or if they 
recapitulate the activity of NS2B/3 in infected cells.  
 
In this study, we have identified novel features of WNV protease substrate-specificity 
using a cell culture-based assay. In efforts to produce virus particles by trans 
complementation, we discovered that the packaging of a WNV sub-genomic RNA by 
DENV structural proteins was strikingly strain-dependent. This phenotype was mapped 
to the substrate specificity of the WNV NS2B/3 protease. WNV NS2B/3 cleavage of the 
DENV2 C protein was substantially reduced by conservative amino acid substitutions at 
the P1’ position of the cleavage site; cleavage was possible with a glycine or serine, but 
not threonine at this site. In contrast, cleavage of the WNV C protein was efficient with 
any of the three residues at the P1’ position. This fine specificity was not predicted by 
studies with recombinant NS2B/3 protease and short peptide substrates (258). We found 
that the sensitivity of WNV NS2B/3 to changes at the P1’ position could be altered when 
residues at the P6-P2 and P2’-P4’ positions were mutated in varying combinations. These 




on protease recognition and has implications for studies of flavivirus protease specificity 
and inhibition. 
 
3.3 Materials and Method 
3.3.1 Cell lines. 
All cell lines were maintained at 37°C and 7% CO2. HEK-293T cells were passaged in 
Dulbecco’s modified Eagle medium (DMEM) containing Glutamax (Invitrogen, 
Carlsbad, CA), supplemented with 7% fetal bovine serum (FBS) (HyClone, Logan, UT) 
and 100U/mL penicillin-streptomycin (PS) (Invitrogen, Carlsbad, CA). Raji cells 
expressing the C-type lectin DC-SIGNR were passaged in RPMI-1640 medium 
containing Glutamax (Invitrogen, Carlsbad, CA), supplemented with 7% FBS and 
100U/mL PS.  
 
3.3.2 Plasmids. 
Plasmids encoding sub-genomic replicons of the WNV lineage II strain 956 (herein 
referred to as WNVrep) and DENV2 strain 16681 (DENVrep) have been described 
previously (259, 260); both were engineered to express a cassette encoding GFP and a 
gene conferring resistance to Zeocin. Plasmids that express the CprME structural genes 
of WNV strain NY99, DENV1 strain Western Pacific-74 (WP), and DENV2 strain 16681 
have been described previously (259, 260). Additionally, the CprME structural genes of 
DENV2 strains New Guinea C (NGC) (GenBank AAA42941) and IQT2913 (GenBank 




CA). Single amino acid mutations were introduced into CprME expression constructs 
using the Quikchange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) 
according to the manufacturer’s instructions. Overlap extension polymerase chain 
reaction (PCR) was used to introduce larger numbers of amino acids changes into the 
NGC CprME C gene, to construct DENV2 NGC/16681 CprME chimeras, and to add a 
V5 tag (GKPIPNPLLGLDST) to the amino-terminus of the C protein in NGC and WNV 
CprME plasmids. All plasmid propagation and cloning procedures were performed using 
Stbl2 bacteria grown at 30°C (Invitrogen, Carlsbad, CA). 
 
3.3.3 Production of RVPs. 
Reporter virus particles (RVPs) were produced by the genetic complementation of a 
DNA-launched, sub-genomic replicon with a CprME expression plasmid, as described 
previously (259, 261). Briefly, pre-plated HEK-293T cells were co-transfected with 
replicon and CprME expression plasmids in a 1:3 ratio by mass using Lipofectamine 
LTX or Lipofectamine 3000 (Invitrogen, Carlsbad, CA) in accordance with the 
manufacturer’s instructions. Transfected cells were incubated in a low glucose 
formulation of DMEM containing 25 mM HEPES (Invitrogen, Carlsbad, CA), 7% FBS, 
and 100U/ml PS. Transfected cells were incubated at 30°C and supernatant was harvested 






3.3.4 Measuring the infectious titer of RVPs. 
The infectious titer of RVPs was assayed using Raji cells expressing DC-SIGNR, as 
described previously (259, 261). Briefly, serial two-fold dilutions of RVP-containing 
supernatant were added to cells, followed by incubation at 37°C for two (WNVrep) or 
three (DENVrep) days. Infection was scored by flow cytometry as the percent of cells 
expressing GFP. To calculate infectious titers, only values on the linear portion of virus 
infectivity titrations were used to solve the following equation: infectious units 
(IU)/sample volume = (percent GFP positive cells) x (number of cells) x (dilution factor). 
 
3.3.5 Quantification of viral RNA. 
The amount of viral RNA in RVP-containing supernatants was measured by quantitative 
reverse transcription PCR (qRT-PCR). Supernatant was treated with recombinant DNase 
I (Roche Diagnostics, Indianapolis, IN), followed by lysis and RNA isolation (EZ1 Virus 
Mini Kit v2.0, Qiagen, Valencia, CA). RNA content was quantified with the Superscript 
III One-step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, 
CA) and primers specific for the 3’ untranslated region of the WNV lineage II replicon 
(262). 
 
3.3.6 Measuring the efficiency of capsid cleavage. 
To measure the efficiency of C protein cleavage by the WNV or DENV protease, V5-
CprME expression constructs were transfected into HEK-293T cells as described above. 




(Thermo Scientific, Waltham, MA) supplemented with protease inhibitors (cOmplete 
mini Protease Inhibitor Cocktail Tablets; Roche Diagnostics, Indianapolis, IN) according 
to the manufacturers’ instructions. Total protein concentration in cell lysates was 
measured using the Thermo Scientific Pierce BCA Protein Assay Kit (Thermo Scientific, 
Waltham, MA) and used to normalize loading of samples for analysis by SDS-PAGE and 
Western blotting. Immunoblots were performed using an anti-V5 mouse monoclonal 
antibody (Invitrogen, Carlsbad, CA) at 1µg/mL, followed by IRDye 800CW Goat anti-
Mouse IgG (1/2500 dilution) (LiCor, Lincoln, Nebraska). Blots were imaged using a 
LiCor Odyssey infrared imaging system (LiCor, Lincoln, Nebraska). C protein cleavage 
was detected by the presence of a band corresponding to the V5-tagged C protein (~13 
kDa), while uncleaved C protein was detected by the presence of a band corresponding to 
CprM (~33 kDa). Cleavage efficiency was quantified by comparing the amount of 
cleaved C (intensity of 13 kDa band) to total C (13 kDa band + 33 kDa band intensities). 
Cleavage efficiency is presented as the percentage of cleaved over total C protein, plus or 
minus one standard error of the mean. 
 
3.3.7 Statistical analyses. 
Statistical analyses were performed using Prism software version 6.0f for Mac OS X 
(GraphPad Software, San Diego, CA). Log10 IU/mL infectious titer values and cleavage 





3.3.8 Surface electrostatic potential calculation. 
Surface electrostatic potential calculations were done with APBS (263) and pdb2pqr 
(264, 265) using default parameters (protein dielectric = 2.0, solvent dielectric = 78.0). 
Images were rendered in PyMOL (266). 
 
3.4 Results 
3.4.1 DENV2 strain-dependent complementation of a WNV sub-genomic replicon. 
Pioneering studies by Alexander Khromykh and colleagues demonstrated that sub-
genomic flavivirus replicon RNAs lacking the structural genes could be encapsidated by 
CprME proteins expressed in trans (267). This genetic complementation results in the 
production of pseudo-infectious virus-like particles capable of only a single round of 
infection, referred to herein as reporter virus particles (RVPs). RVPs have been used 
extensively to study flavivirus biology (268-273) and virus-antibody interactions (32, 
130, 260, 261, 274), and as tools to screen antiviral compounds (244, 275, 276). The 
mechanism of flavivirus RNA packaging is not well understood and appears to be 
relatively non-selective. Replicon RNAs of one flavivirus can be packaged by structural 
genes derived from another flavivirus (31, 259, 277, 278). Additionally, several flavivirus 
vaccine candidates are chimeric viruses in which the structural proteins of one virus are 
inserted into the genomic background of a heterologous virus type (reviewed by (279)). 
To study mechanisms of flavivirus neutralization, our laboratory has produced RVPs by 
complementation of a WNV replicon (WNVrep) with structural genes derived from 




titer RVP stocks have been generated by complementation of WNVrep with the structural 
genes of DENV2 strain 16681 (33, 259).  
 
To expand the DENV2 strains available for study using this approach, we generated 
CprME structural gene constructs for the strains New Guinea C (NGC) and IQT2913. 
DENV2 NGC is the strain from which the DENV2 component of the NIAID tetravalent 
vaccine candidate was derived (15). IQT2913 is an isolate from Iquitos, Peru (280). 
Figure 3.1A shows RVP titers generated by complementation of the WNV replicon with 
CprME from DENV2 NGC and IQT2913, as well as from flaviviruses previously shown 
to result in infectious RVPs (DENV2 16681, DENV1 Western Pacific-74 (WP) strain, 
and the NY99 strain of WNV). Complementation with CprME from WNV, DENV1, and 
DENV2 16681 produced comparable RVP titers that peaked ~72-96 hours post-
transfection, similar to previous observations (259). Mean titers for WNV, DENV1, and 
DENV2 16681 RVPs collected at 72 hours post-transfection ranged from 1x106 to 4x106 
IU/mL (n=3) (Figure 3.1B). Conversely, complementation of the WNV replicon with 
CprME from DENV2 strains NGC and IQT2913 resulted in no detectable RVP 
production (n=3) (Figure 3.1A and 3.1B). These results were surprising, as DENV2 
16681 shares 98% and 97% amino acid identity with strains NGC and IQT2913, differing 
by 17 and 24 amino acid residues within CprME, respectively. Analysis of the RNA 
content of DENV2 NGC and IQT2913 RVP preparations revealed >1,000-fold lower 
RNA content than DENV2 16681 RVP-containing supernatants produced in parallel 





Figure 3.1 DENV2 strain-dependent complementation of a WNV sub-genomic replicon. (A-C) RVPs 
were produced by complementation of a GFP-expressing WNV replicon (WNVrep) and a CprME plasmid 
encoding the structural genes of WNV (NY99), DENV1 (WP), or DENV2 (strains 16681, NGC, and 
IQT2913). (A) RVPs were harvested at the times indicated post-transfection and used to infect Raji DC-
SIGNR cells. Infection was scored by GFP expression two days post-infection using flow cytometry. Error 
bars represent the range of duplicate infections. The results shown are representative of three independent 
experiments. (B) The infectious titer of RVPs collected 72hr post-transfection was determined. Error bars 
represent the standard error of the mean for three independent experiments. (C) RVPs collected 72hr post-
transfection were analyzed for viral RNA content by qRT-PCR. Error bars represent the standard error of 





































































































genes from DENV2 strains NGC or IQT2913 reflected a defect prior to the release of 
virus particles into the supernatant.  
 
We next performed complementation experiments with a DENV2 sub-genomic replicon 
of similar design (DENVrep). RVPs produced using this replicon resulted in comparable 
titers for all three DENV2 strains (16681, NGC, and IQT2913), with mean titers ranging 
from 1x105 to 5x105 IU/mL at 120 hours post-transfection (n=3) (Figure 3.2A and 
3.2B). As noted previously (259), RVP production using the DENV replicon was delayed 
(Figure 3.1A versus 3.2A) and less efficient (Figure 3.1B versus 3.2B) as compared to 
experiments with WNVrep.  
 
3.4.2 The C protein governs DENV2 RVP production following WNV replicon 
complementation. 
To determine the molecular basis of the DENV2 strain-specific RVP production, we 
created chimeras of DENV2 16681 and DENV2 NGC structural proteins (Figure 3.3A). 
Each chimera was evaluated in complementation experiments with the WNV replicon. 
RVP production studies revealed that all CprME chimeras containing the C gene of 
16681, regardless of the origin of the prM or E genes, resulted in robust RVP titers (mean 
titers >105 IU/mL, n=3). In contrast, all CprME chimeras encoding the NGC C gene 
resulted in undetectable RVP production (n=3) (Figure 3.3B). These data reveal a critical 







Figure 3.2 DENV2 complementation of a DENV sub-genomic replicon. (A and B) RVPs were 
produced by complementation of a GFP-expressing DENV replicon (DENVrep) with DENV2 CprME 
(strains 16681, NGC, and IQT2913). (A) RVP samples collected at the indicated times post-transfection 
were analyzed for infectivity of Raji DC-SIGNR cells. Error bars represent the range of duplicate 
infections. The results shown are representative of three independent experiments. (B) The infectious titer 
of RVPs collected at 120hr post-transfection was determined. Error bars represent the standard error of the 























































Figure 3.3 Genetic basis of DENV2 strain-dependent complementation of the WNV sub-genomic 
replicon. (A) Schematics of DENV2 16681/NGC CprME chimeras, with genes from 16681 in grey and 
genes from NGC in black and white pattern. Locations of amino acid sequence variation between the two 
strains are indicated by “+” marks. (B-D) RVPs were produced by WNVrep complementation with the 
DENV2 CprME construct indicated on the x-axis. Infectious RVP titer was determined at 72hr post-
transfection; error bars represent the standard error of the mean for three independent experiments. 
Infectious RVP titers are shown for (B) DENV2 16681, NGC, and the 16681/NGC CprME chimeras shown 
in panel A, (C) DENV2 16681, NGC, and NGC containing point mutations R9K or T101S in the C protein, 
and (D) DENV2 16681 and 16681 C protein mutant S101T. (E) An alignment of sequences surrounding 
the NS2B/3 cleavage site in the C protein for DENV2 strains 16681, NGC, and IQT2913. 





























































16681 M L N I L N R R R R S A G M I I M L I P
NGC M L N I L N R R R R T A G M I I M L I P
IQT2913 M L N I L N R R R R T A G M I I M L I P






The C proteins of DENV2 16681 and NGC differ at only two amino acid residues 
(residues 9 and 101). We created NGC variants encoding a single substitution at these 
positions to correspond to the amino acid found in 16681, and evaluated them in RVP 
production experiments with WNVrep. Complementation with wild-type (WT) NGC and 
the NGC R9K variant resulted in undetectable RVP titers (n=3). In contrast, the T101S 
mutation in the NGC background resulted in RVP production similar to titers obtained 
with 16681 (>105 IU/mL, p=0.36, n=3) (Figure 3.3C). A similar pattern was observed 
following the introduction of mutation T101S into the DENV2 IQT2913 C protein (data 
not shown). Conversely, the reciprocal S101T mutation in the 16681 C protein rendered 
this construct incapable of RVP production following complementation of the WNV 
replicon (Figure 3.3D). Together, these results identify C protein residue 101 as the 
determinant of compatibility between the structural genes of DENV2 and a WNV 
replicon RNA during virus particle production.  
 
3.4.3 WNV NS2B/3 cannot cleave the DENV2 C protein when a threonine occupies 
the P1’ position. 
During polyprotein processing, NS2B/3 cleaves the C protein immediately after residue 
100, removing the C-terminal signal sequence and liberating it from its membrane 
anchor. C protein residue 101 identified above is located immediately downstream of the 
scissile bond in the P1’ position of the cleavage site (Figure 3.3E), and therefore has the 
potential to impact cleavage by the WNV protease. To investigate this hypothesis, we 
developed an assay to measure C protein cleavage in cells harboring a replicating 




NGC CprME expression constructs (V5-CprME), enabling quantitation of NS2B/3 
cleavage efficiency in RVP-producing cells by Western blot. Using this system, capsid 
cleavage resulted in the production of a V5-tagged C protein that is considerably smaller 
than its uncleaved C-prM precursor (13 kDa and 33 kDa, respectively). Cleavage studies 
in HEK293T cells co-transfected with the WNV replicon and WT NGC CprME genes 
resulted in no detectable cleaved C protein in cell lysates. In contrast, partial cleavage of 
NGC T101S (the 16681 P1’ residue) and NGC T101G (the WNV P1’ residue) was 
observed in experiments performed in parallel (31±16% and 63±12%, respectively; n=4) 
(Figure 3.4A and 3.4B). These results correlated well with the ability of these structural 
gene constructs to produce infectious RVPs by complementation (Figure 3.4C versus 
Figure 3.1B and 3.2B). RVP production with the WT NGC V5-CprME construct 
resulted in undetectable titers, whereas NGC constructs with T101S or T101G mutations 
at the P1’ site enabled efficient RVP release (>105 IU/mL, n=2). By comparison, 
cleavage experiments using the DENV replicon resulted in efficient cleavage of the C 
protein regardless of whether the amino acid at residue 101 was a T, S, or G (>90% 
cleaved C, n=4) (Figure 3.4A and 3.4B). RVP titers in the corresponding supernatants 
were similar for all three structural gene constructs (~3x103 IU/mL, n=2). These results 
demonstrated that even chemically conservative amino acid variation at the P1’ position 
modulates cleavage of the DENV C protein and RVP production in cells replicating a 






Figure 3.4 Cleavage of the C protein of DENV2 NGC T101 mutants by WNV and DENV NS2B/3. An 
amino-terminal V5 tag was added to the C proteins of WT NGC, NGC T101S, and NGC T101G CprME 
constructs. The V5 tagged CprME constructs were used in complementation experiments with WNVrep 
and DENVrep. Cell lysates were harvested at 48hr post-transfection and analyzed by SDS-PAGE and 
Western blotting with an anti-V5 mAb. (A) A representative blot is shown. The lower band corresponds to 
cleaved C (~13 kDa), while the upper band corresponds to uncleaved CprM (~33 kDa). (B) Mean cleavage 
efficiency of the C protein from four independent experiments; error bars represent the standard error of the 
mean. (C) Mean infectious titer of RVPs harvested prior to cell lysate collection (48hr post-transfection). 
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3.4.4 WNV NS2B/3 efficiently cleaves the WNV C protein when a threonine occupies 
the P1’ position. 
Because a T residue in the P1’ position of the DENV2 NGC C protein cleavage site 
prevents processing by the WNV NS2B/3 protease, we hypothesized that introducing a T 
into the P1’ position (residue 106) of the WNV C protein cleavage site would have a 
similar phenotype. Surprisingly, complementation of the WNV replicon with a WNV 
G106T variant resulted in efficient RVP production (3x106 IU/mL, n=3) (Figure 3.5A), 
with only a 0.5 log reduction in titer compared to WT WNV (p=0.015, n=3). Likewise, a 
WNV G106S variant also supported RVP titers similar to WT WNV (p=0.18, n=3). 
Biochemical studies revealed that WNV protease cleavage efficiency of all three 
constructs was similar (Figure 3.5B and 3.5C, n=3, p>0.05 for all comparisons). 
Altogether, these data demonstrate that a threonine in the P1’ position of the C protein 
cleavage site impacts WNV NS2B/3 protease efficiency in a strikingly context-dependent 
manner.  
 
3.4.5 The specificity of WNV NS2B/3 at the P1’ position is influenced by 
surrounding residues. 
We next investigated how the sequence surrounding the protease cleavage site affected 
WNV protease specificity at the P1’ position. We substituted residues adjacent to the 
incompatible threonine at the P1’ position of NGC capsid to those corresponding to the 
WNV capsid (Figure 3.6A). Cleavage of each NGC C protein variant was measured by 
Western blot of cells expressing the WNV replicon; the efficiently cleaved NGC T101G 





Figure 3.5 Cleavage of the C protein of WNV G106 mutants by WNV NS2B/3. RVPs were produced 
by complementation of WNVrep with CprME derived from wild-type WNV (WT) or from WNV 
containing mutations at C protein residue G106 (the P1’ position of the WNV C protein cleavage site). (A) 
Shown is the mean infectious RVP titer of supernatant collected 72hr post-transfection; error bars represent 
the standard error of the mean for three independent experiments. (B and C) An amino-terminal V5 tag 
was added to the C protein in the WNV CprME constructs (WT, G106S, and G106T). Following 
complementation of WNVrep with the WNV V5-tagged CprME constructs, cell lysates were collected at 
48hr post-transfection and analyzed by SDS-PAGE and Western blotting with an anti-V5 mAb. (B) A 
representative blot is shown. The minor mobility shift for the band corresponding to the C protein of 
G106T was not observed in all independent repeats. (C) Mean cleavage efficiency of the WNV C protein; 
error bars represent the standard error of the mean from three independent experiments.   
 














































Figure 3.6 Effect of multiple mutations surrounding C protein residue T101 on WNV NS2B/3 
cleavage of the NGC C protein. (A) Sequence alignment of the C protein cleavage site of WNV, DENV2 
NGC, and DENV2 NGC mutants. Highlighted in gray is the P1’ residue; highlighted in black are the 
substitutions from the WNV cleavage site introduced into each variant. The numbering at the top 
corresponds to the location in the DENV2 NGC C protein amino acid sequence. (B-D) V5-tagged CprME 
constructs of DENV2 NGC containing a mutation at the indicated C protein cleavage site were used in 
complementation experiments with WNVrep. Cell lysates were collected and analyzed by SDS-PAGE and 
subjected to Western blotting with an anti-V5 mAb. For the NGC variants from panel A, shown is a 
representative blot (B), with the mean efficiency of C protein cleavage (C) and mean infectious RVP titer 
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when positions P4-P2’ (55±9%) and P6-P4’ (86±6%) were mutated (Figure 3.6B and 
3.6C). Mutations at residues flanking just one side of the cleavage site were poorly 
cleaved (14±3% and 13±7% for mutants P2’-10’ and P10-P2 respectively). Notably, the 
cleaved C protein of mutant P2’-P10’ migrated more slowly during gel electrophoresis 
than C protein expressed from other NGC constructs (Figure 3.6B). In this construct, the 
order of cleavage may be uncoupled by mutations within the signal sequence, which have 
the potential to impact the display of the capsid-signal sequence junction and result in a 
cleaved C protein that retains a C-terminal signal sequence (233). As detailed above, the 
efficiency of C protein cleavage directly impacted the release of infectious virus particles. 
The relatively efficiently cleaved capsid variants supported virus production, including 
NGC T101G (9x105 IU/mL), mutant P4’-P2’ (7x104 IU/mL; 13-fold reduction from 
T101G), and mutant P6-P4’ (9x104 IU/mL; 10-fold reduction from T101G), while low-
to-undetectable titers for mutants P2’-10’ and P10-P2 (<102 IU/mL) were achieved 
(Figure 3.6D). These results suggest that amino acids directly surrounding the cleavage 
site influence the ability of WNV NS2B/3 to cleave a substrate when a T occupies the P1’ 
position. 
 
Our data suggested that the ability of WNV NS2B/3 to cleave DENV C proteins with a 
threonine at the P1’ position can be influenced by residues between P4 and P2’. 
Therefore, we constructed NGC C protein variants with single amino acid substitutions 
(at the P4, P3, P2, or P2’ position) to determine if individual substitutions influence 
WNV NS2B/3 specificity. Unlike the efficient C protein cleavage detected for NGC 




a single mutation at either P4, P3, P2, or P2’ was observed (n=3, p>0.25 for WT NGC vs. 
each mutant) (Figure 3.7A and 3.7B). Notably, among these constructs, the C protein of 
the P2’ mutant was most efficiently cleaved (10±3%) (Figure 3.7B), and supported RVP 
production (5x104 IU/mL; a 51-fold reduction from T101G) (Figure 3.7C) to levels 
similar to that observed when multiple residues were changed (mutants P6-P4’ and P4-
P2’, Figure 3.6D). 
 
The difference in cleavage efficiency of the P6-P4’ and P4-P2’ variants (Figure 3.6D) 
suggests a role for residues farther from the scissile bond studied above. Of interest, the 
P5 and P3’ residues differ in charge between WNV and DENV. We constructed 
additional NGC C protein variants with single amino acid substitutions at the P6, P5, P3’, 
and P4’ positions and evaluated the efficiency of C protein cleavage following 
complementation with the WNV replicon. Complementation with mutants P6 and P4’ 
resulted in inefficient cleavage (4±1% and 9±5%, respectively) (Figure 3.7D and 3.7E) 
and low but detectable RVP titers (7x103 IU/mL and 3x104 IU/mL; 59- and 15-fold 
reductions from T101G titers for mutants P6 and P4’, respectively) (Figure 3.7F). For 
mutants P5 and P3’, neither cleaved C protein nor infectious RVPs were detectable 
(Figure 3.7D-F). 
  
Altogether, these results indicate that the interactions that mediate WNV NS2B/3 
specificity for the P1’ site involve multiple surrounding residues. Mutations at the P6, 
P2’, and P4’ positions individually had a minor effect on C protein cleavage compared to 





Figure 3.7 Effect of individual mutations surrounding C protein residue T101 on WNV NS2B/3 
cleavage of the NGC C protein. V5-tagged CprME constructs of DENV2 NGC containing a mutation at 
the indicated C protein cleavage site (to match the corresponding residue in the WNV cleavage site) were 
used in complementation experiments with WNVrep. Cell lysates were collected and analyzed by SDS-
PAGE and subjected to Western blotting with an anti-V5 mAb. For mutants P4, P3, P2, and P2’, shown is a 
representative blot (A), with the mean efficiency of C protein cleavage (B) and mean infectious RVP titer 
(C) from three independent experiments; error bars represent the standard error of the mean. For mutants 
P6, P5, P3’, and P4’, shown is a representative blot (D), with the mean efficiency of C protein cleavage (E) 
and mean infectious RVP titer (F) from three independent experiments; error bars represent the standard 







































































































Little is known about the specificity of the flavivirus NS2B/3 protease in the context of 
viral RNA replication or authentic viral polyprotein substrates (281). Most studies to 
define protease cleavage site specificity employ short (3-8 amino acids) synthetic peptide 
substrates and covalently linked and truncated forms of NS2B and NS3 (250-258). 
Furthermore, these experiments are performed in the absence of membranes, at basic pH 
(~pH 9), and in the presence of detergents and high concentrations of glycerol. These 
biochemical approaches have identified a requirement for dibasic residues at P1 and P2 
and a small side chain at the P1’ position of the cleavage site, though preferences for 
particular residues within that motif exist and distinct specificities have been noted 
between viruses. WNV NS2B/3 has been shown to preferentially cleave sites with a K at 
P2, whereas DENV NS2B/3 most efficiently cleaves sites with an R at this position. In 
contrast, WNV and DENV NS2B/3 proteases both preferentially cleave sites with an R 
over a K at the P1 position (250, 258, 282). These studies have indicated that WNV 
NS2B/3 has a strict preference for G at both the P1’ and P2’ positions, while DENV 
NS2B/3 is less selective and can cleave substrates with almost any amino acid at P1’ and 
P2’ (258). Another study, however, observed a narrower specificity of the DENV 
protease at the P1’ position (restricted to small, polar amino acids with a strong 
preference for S) and at the P2’ position (a weak preference for acidic residues) (282).  
 
How substrate residues outside of the active site recognition site impact cleavage 
efficiency has not been well explored for flavivirus proteases. Allosteric and subsite 




(283)). Allosteric cooperativity occurs when the binding of substrate residues to a 
protease outside of the active site affects proteolytic efficiency. Subsite cooperativity 
posits that individual subsite binding may be positively or negatively influenced by 
binding of surrounding subsites (reviewed in (283)). Both processes have been shown to 
contribute to HIV-1 protease recognition (284-287). As discussed above, prior studies of 
the WNV NS2B/3 employed short peptide substrates that do not extend significantly 
beyond the active site, potentially limiting their utility for identifying all the interactions 
that impact protease specificity.  
 
To investigate the effect of cleavage site context on WNV NS2B/3 substrate specificity, 
we studied WNV NS2B/3 processing of DENV and WNV C proteins. WNV NS2B/3 
cleaved the DENV2 C protein when a G, but not a T, occupied the P1’ position. In 
contrast, when the P1’ residue of the WNV C protein cleavage site was mutated from a G 
to a T, we observed efficient WNV NS2B/3 cleavage, indicating that a T at P1’ is 
permissive for cleavage only in the context of certain substrates. This context-dependent 
cleavage specificity could be a result of either allosteric or subsite cooperativity (or both), 
as the WNV and DENV2 C proteins have sequence differences at residues both within 
and outside of the protease binding site.  
 
To study the effect of subsite cooperativity on WNV protease specificity, we introduced 
mutations in a DENV2 CprME construct at residues surrounding the C protein cleavage 
site. While keeping a T constant at the P1’ position (which results in uncleaved C protein 




match the WNV C protein cleavage site. We found that WNV NS2B/3 was able to 
efficiently cleave the DENV2 C protein containing a T at the P1’ position when the P4, 
P3, P2, and P2’ positions were mutated simultaneously. When the P6, P5, P3’ and P4’ 
positions were additionally mutated, cleavage efficiency was further enhanced. Thus, the 
sequence context within the active site binding site of the substrate greatly impacts WNV 
NS2B/3 specificity for the P1’ residue. However, when the P6, P5, P4, P3, P2, P2’, P3’, 
and P4’ mutations were introduced separately, their effect on the efficiency of DENV2 C 
protein cleavage by the WNV protease was greatly diminished. Thus, the interactions that 
mediate the context-dependent specificity of WNV NS2B/3 at the P1’ position are likely 
due to the influence of multiple substrate residues.  
 
Notably, one in vitro study observed strict specificity of WNV NS2B/3 for a G at P1’ 
(258). This finding is not consistent with the observation that, while most WNV NS2B/3 
cleavage sites do contain a G at P1’, the P1’ position of the cleavage site at the 
NS3/NS4A junction is occupied by an S. It also contradicts our finding that the WNV and 
DENV2 C proteins were cleaved by the WNV protease when an S occupied the P1’ 
position. Several differences in experimental design between the studies could account 
for this discrepancy, including assay conditions (biochemical vs cell-based assay), 
NS2B/3 source (recombinant, truncated NS2B/3 vs. full-length NS2B/3 from the 






Structural basis for WNV NS2B/3 substrate specificity. Efficient peptide cleavage 
requires accurate placement of the scissile peptide bond in the active site. A view of 
substrate binding is available in crystal structures for inhibitor-bound WNV NS2B/3 
(238, 288, 289) and DENV NS2B/3 (290). The pocket in NS2B/3 occupied by the 
substrate P1’ side chain (the S1’ subsite) is lined by the side chains of NS3 residue 36 
(DENV I36, WNV A36) and the catalytic histidine (NS3-H51) (238). In structures of 
both WNV and DENV NS2B/3, the P1’ side chain of a protein inhibitor binds identically 
to the small and relatively hydrophobic S1’ subsite (238, 290). In contrast, the S2’ subsite 
for the substrate P2’ side chain is a large, open pocket on the enzyme surface between the 
side chains of NS3 residues 34 and 131. Here the structures differ (NS3 Y34 in WNV vs. 
T34 in DENV; NS3 P131 in WNV vs. K131 in DENV). The structures are consistent 
with the data presented herein that substrate sequences flanking the cleavage site play a 
role in specificity (290). Our data are also consistent with other observations that NS3-
131-132 contributes to specificity of the P2’ position, as mutating WNV NS3-P131 and 
NS3-T132 to match the DENV sequence (P131K+T132P) shifted the specificity of WNV 
NS2B/3 to that of DENV NS2B/3 (291). Interactions between protease and substrate on 
the non-prime site of the scissile bond involve the S2 and S3 pockets of the active site, 
and are occupied by the P2 and P3 positions of the substrate, respectively. Like the 
situation for the substrate P1’ site, the substrate P2 and P3 side chains bind WNV and 
DENV NS3 identically in the S2 and S3 subsites (238, 289). Substrate-enzyme 






The subsite cooperativity observed in our study may be a result of restrictions on 
substrate size by WNV NS2B/3, where the WNV NS2B/3 preference for the smaller 
substrate residues at P1’ (G>T) and P2 (K>R) can be overcome by the introduction of 
smaller residues at neighboring positions. We have shown that WNV NS2B/3 cleavage of 
substrates with a T in the P1’ position is dependent on the surrounding residues. Notably, 
when the P4, P3, P2, and P2’ positions were mutated to the smaller but chemically 
similar amino acids found in the WNV C protein cleavage site, WNV NS2B/3 could 
cleave the DENV2 NGC C protein substrate with a P1’ threonine. 
  
Our data together with the available structures show that proper positioning of the peptide 
substrate is influenced by NS3 interaction with flanking residues at a distance of up to six 
N-terminal and four C-terminal of the target peptide bond. Although partial activity can 
be restored with a single substitution at the P1’ site, efficient cleavage of natural substrate 
requires multiple substrate-enzyme interactions. Consistent with our data, WNV and 
DENV NS2B/3 structures have strikingly different electrostatic surface potential near the 
active site (Figure 3.8). WNV NS2B/3 has a more negatively charged surface in the 
region surrounding the substrate entrance, while DENV NS2B/3 has a more 
electropositive surface. The more negative surface of WNV NS2B/3 outside of the active 
site may account for the increased cleavage efficiency we observed when the P6, P5, P3’ 
and P4’ positions were mutated in addition to the P4-P2’ positions in NGC mutant P6-
P4’, as the P5 and P3’ positions now contained positively charged lysine residues. While 






Figure 3.8 Electrostatic surface potential of the WNV and DENV proteases. The surfaces of inhibitor-
bound (A) WNV NS2B/3 (PDB 3E90) (289) and (B) DENV NS2B/3 (PDB 3U1I) (290) are colored 








the NGC C protein, cooperative effects from multiple residues surrounding the cleavage 
site could mediate cleavage. 
 
Our results indicate that subsite cooperativity involving multiple residues within the P6-
P2 and P2’-P4’ positions influences the specificity of the WNV protease at the P1’ 
position. This finding has implications for the design of experiments to probe NS2B/3 
substrate specificity, as the substrate selected for specificity profiling may drastically 
affect the results of the screen. Furthermore, molecular details of substrate specificity can 





Chapter 4: The type-specific neutralizing antibody response 
elicited by a dengue vaccine candidate is focused on two amino 




Dengue viruses are mosquito-borne flaviviruses that circulate in nature as four distinct 
serotypes (DENV1-4). These emerging pathogens are responsible for more than 100 
million human infections annually. Severe clinical manifestations of disease are 
predominantly associated with a secondary infection by a heterotypic DENV serotype. 
The increased risk of severe disease in DENV-sensitized populations significantly 
complicates vaccine development, as a vaccine must simultaneously confer protection 
against all four DENV serotypes. Eliciting a protective tetravalent neutralizing antibody 
response is a major goal of ongoing vaccine development efforts. However, a recent large 
clinical trial of a candidate live-attenuated DENV vaccine revealed low protective 
efficacy despite eliciting a neutralizing antibody response, highlighting the need for a 
better understanding of the humoral immune response against dengue infection. In this 
study, we sought to identify epitopes recognized by serotype-specific neutralizing 
antibodies elicited by monovalent DENV1 vaccination. We constructed a panel of over 
50 DENV1 structural gene variants containing substitutions at surface-accessible residues 
of the envelope (E) protein to match the corresponding DENV2 sequence. Amino acids 
that contribute to recognition by serotype-specific neutralizing antibodies were identified 
                                                
3 Adapted from reference 261. VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, 
Pierson TC. 2013. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate 




as DENV mutants with reduced sensitivity to neutralization by DENV1 immune sera, but 
not cross-reactive neutralizing antibodies elicited by DENV2 vaccination. We identified 
two mutations (E126K and E157K) that contribute significantly to type-specific 
recognition by polyclonal DENV1 immune sera. Longitudinal and cross-sectional 
analysis of sera from 24 participants of a phase I clinical study revealed a markedly 
reduced capacity to neutralize a E126K/E157K DENV1 variant. Sera from 77% of 
subjects recognized the E126K/E157K DENV1 variant and DENV2 equivalently (<3-
fold difference). These data indicate the type-specific component of the DENV1 
neutralizing antibody response to vaccination is strikingly focused on just two amino 
acids of the E protein. This study provides an important step towards deconvoluting the 
functional complexity of DENV serology following vaccination. 
 
4.2 Introduction 
Dengue virus (DENV) is a mosquito-transmitted flavivirus responsible for 390 million 
human infections each year (1). Four related serotypes (DENV1-4) circulate in virtually 
all tropical and sub-tropical regions of the world (2). While DENV infection is often 
subclinical, clinical symptoms of dengue fever (DF) include a self-limiting febrile illness, 
myalgia, rash, and retro-orbital pain (3). A more severe clinical illness (dengue shock 
syndrome/dengue hemorrhagic fever) involving capillary leakage, thrombocytopenia, and 
hemorrhage has been associated with secondary infections by a heterologous DENV 
serotype and higher viral loads in vivo (86, 292). The incidence of severe DENV disease 




areas (2, 8). Currently, there are no specific treatments or approved vaccines for DENV 
infection.  
 
Flaviviruses encapsidate a single-stranded RNA genome of positive-sense polarity. This 
~11kb genomic RNA is translated as a single open reading frame that is cleaved in 
infected cells by cellular and viral proteases into at least ten proteins (293). The virus 
encodes three structural proteins (envelope (E), premembrane (prM), and capsid (C)) that 
associate with a lipid envelope and the viral genome to form the virion (44). Flavivirus 
assembly occurs on virus-induced membranes derived from the endoplasmic reticulum 
(ER) (19, 22, 23, 294, 295), resulting in the budding of non-infectious immature virus 
particles into the lumen. The E protein of immature virions exists as heterotrimeric spikes 
in complex with the prM protein; sixty of these spikes are organized on the virion with 
icosahedral symmetry (29, 36, 37). During egress through the secretory pathway, prM is 
cleaved by a cellular furin-like protease to generate the mature infectious virus particle 
(26-28). Mature virions are characterized by a dense array of antiparallel E protein dimers 
orientated roughly parallel to the surface of the virion (39-41). In many cases, this 
arrangement of E proteins imposes steric constraints for epitope recognition by antibodies 
(54, 296). The virion maturation process is inefficient for many mosquito-borne 
flaviviruses, including DENV. Partially mature viruses with structural features of both 
mature and immature particles may be infectious and differentially interact with 





The humoral response plays an important role in protection against flaviviruses (reviewed 
in (297)). Development of a neutralizing antibody response is an established correlate of 
protection following vaccination against yellow fever virus (YFV), Japanese encephalitis 
virus (JEV), and tick-born encephalitis virus (TBEV) (192-195). Passive transfer of 
monoclonal antibodies (mAbs) is protective in several animal models of flavivirus 
infection, including DENV (47, 48, 142, 197-199). The flavivirus E protein is the 
principal target of neutralizing antibodies (42). Studies with murine and human mAbs 
have identified neutralizing epitopes on all three structural domains of E (DI-III) (47-56, 
296, 298-300). Recent studies with human mAbs suggest the antibody repertoire may 
differ from that observed in mice (50, 57-60, 301), and have identified a quaternary 
epitope composed of surfaces on two adjacent E proteins (56-58). Antibodies that bind 
prM also have been identified frequently in studies of human mAbs and typically possess 
limited neutralization potential in vitro (50, 59-61). Beyond a capacity to directly 
neutralize the infectivity of virions, antibodies may protect the host via effector functions 
orchestrated by the constant region of the antibody molecule (136, 302-304).  
 
Development of a DENV vaccine has been a focus of considerable effort for decades. 
While the dramatic success of other flavivirus vaccines (193, 305, 306) and the 
pioneering work of Sabin and colleagues (11) suggest effective DENV vaccination is 
possible, several unique challenges exist. A DENV vaccine must simultaneously protect 
against four different viruses. In addition, vaccination must not sensitize the recipient to 
more severe manifestations of disease in the event of breakthrough. The antibody 




(CR) antibodies that may vary significantly with respect to their capacity to neutralize 
virus infection (47-49, 215, 216, 307). CR antibodies are hypothesized to contribute to 
severe clinical outcomes of DENV infection via a process called antibody-dependent 
enhancement of infection (12). The extensive cross-reactivity of the DENV antibody 
response complicates serological studies of these viruses and the identification of 
immune correlates of protection (308, 309). For example, a recent large phase IIb trial of 
a live-attenuated tetravalent DENV vaccine revealed modest protective efficacy (~30% 
overall) with no protection at all observed for DENV2 (224). Importantly, despite the 
absence of protection, vaccine-induced neutralizing antibody was observed for DENV2. 
Whether this increase in neutralizing titer was associated with a TS- or CR-response is 
unknown. This trial underscores the importance of understanding the functional 
complexity of the DENV antibody response.  
 
In this study we sought to identify the immunodominant epitopes recognized by TS-
neutralizing antibodies elicited by DENV vaccination of humans. We constructed 
libraries of DENV1 variants containing substitutions in the E protein at surface exposed 
residues that differ between the DENV1 and DENV2 components of the NIAID 
tetravalent vaccine candidate (13). We then screened this library for a reduction in 
sensitivity to neutralization by sera from DENV1 vaccine recipients, but not DENV2 
immune sera from vaccinated subjects. Remarkably, these studies identified two amino 
acids (E126 and E157) that when mutated significantly reduced the DENV1 TS-
neutralizing response of more than 77% of recipients of a monovalent DENV1 vaccine. 




TS-neutralizing response and provide insight into the complexity of the DENV humoral 
response.  
 
4.3 Materials and Methods 
4.3.1 Cell lines. 
All cell lines were maintained at 37°C in the presence of 7% CO2. HEK-293T cells were 
passaged in complete Dulbecco’s modified Eagle medium (DMEM) containing Glutamax 
(Invitrogen, Carlsbad, CA), supplemented with 7.5% fetal bovine serum (FBS) 
(HyClone, Logan, UT) and 100 U/ml penicillin-streptomycin (PS) (Invitrogen, Carlsbad, 
CA). Raji-DCSIGNR cells were passaged in RPMI-1640 medium containing Glutamax 
(Invitrogen, Carlsbad, CA), supplemented with 7.5% FBS and 100 U/ml PS.  
 
4.3.2 DENV immune sera and antibodies. 
Sera from recipients of phase I studies of candidate monovalent DENV1 or DENV2 
vaccines were obtained for study. Initial screening studies were performed using sera 
pooled from two or three recipients of the DENV1 and DENV2 vaccines, respectively, 
collected 2-3 years post-vaccination. Neutralizing antibody responses from 24 
participants of a DENV1 vaccine study were studied individually (310); sera were 





4.3.3 Ethics Statement. 
Clinical studies were conducted at the Center for Immunization at the Johns Hopkins 
Bloomberg School of Public Health under an investigational new drug application 
reviewed by the United States Food and Drug Administration. The clinical protocol and 
consent form were reviewed and approved by the NIAID Regulatory Compliance and 
Human Subjects Protection Branch, the NIAID Data Safety Monitoring Board, the 
Western Institutional Review Board, and the Johns Hopkins University Institutional 
Biosafety Committee (ClinicalTrials.gov identifiers; NCT00473135, NCT00920517). 
Written informed consent was obtained from each participant in accordance with the 
Code of Federal Regulations (21 CFR 50) and International Conference on 
Harmonisation guidelines for Good Clinical Practice (ICH E6). 
 
4.3.4 Plasmids. 
Plasmids encoding a WNV sub-genomic replicon and DENV1 WP CprME structural 
genes have been described previously (138, 259, 260). An expression construct of the 
CprME gene of the DENV2 NGC strain was constructed using similar methods and will 
be described elsewhere (VanBlargan and Pierson, unpublished data). Plasmids encoding 
structural gene variants with up to three amino acid substitutions were produced by site-
directed mutagenesis using the Quikchange Mutagenesis kit (Stratagene, La Jolla, CA) 
according to the manufacturer’s instructions. All plasmids used in this study were 





4.3.5 Selection of DENV1 residues for mutagenesis. 
To identify amino acids recognized by TS-neutralizing antibodies in vaccine sera, we 
targeted residues for mutagenesis that differed between the DENV1 and DENV2 strains 
used in the NIAID tetravalent vaccine candidate. The envelope proteins of the DENV1 
WP strain and the DENV2 NGC strain differ by 158 amino acids. As a metric to narrow 
our mutagenesis efforts, we focused on residues predicted to be exposed on the surface of 
the virion. Surface accessibility was estimated using solvent accessible surface areas of 
the residues determined from the crystal structure of the E protein dimer (PDB ID: 
10AN), with a cut-off value of 30 Å2 (UCSF Chimera package) (311, 312). Residues 
were then further restricted by modeling the dimer onto the mature virion (PDB ID: 
1THD) (313). Residues exposed on the surface of the virion were then selected, 
narrowing the list of candidates to 68 (313). Admittedly, because our selection scheme 
was based on a static model of the mature virion, this minimalist approach to selecting a 
core panel of residues had the potential to be complicated by the structural heterogeneity 
and dynamics of the virus particle. Virion structure is influenced by the maturation state 
and structural dynamics of the virion (32, 36, 138). Both have the potential to increase the 
number of residues that may contribute to TS-antibody recognition. Additionally, 
structural studies of DENV2 at 37°C revealed the virus not only becomes considerably 
more heterogeneous at this temperature but also appears to adopt a distinct structure(s) at 





4.3.6 Production of DENV RVPs. 
DENV RVPs were produced by complementation of a WNV replicon with plasmids 
encoding the structural genes of DENV as described previously (138, 259). Briefly, pre-
plated HEK-293T cells were transfected with plasmids encoding the WNIIrepG/Z 
replicon and DENV CprME in a 1:3 ratio by mass, using Lipofectamine LTX 
(Invitrogen, Carlsbad, CA) in accordance with the manufacturer’s instructions. Four 
hours post-transfection, culture media were replaced with a low-glucose formulation of 
DMEM containing 25 mM HEPES (Invitrogen, Carlsbad, CA), 7% FBS, and 100 U/ml 
PS, and incubated at 30°C. RVP-containing supernatant was collected at multiple time 
points starting at 72 hours post-transfection, filtered using a 0.22µm syringe filter, and 
stored at -80°C. The low-glucose DMEM was replenished after each harvest.   
 
To generate more homogenous populations of RVPs with low to undetectable uncleaved 
prM, complementation experiments were modified to include a plasmid expressing 
human furin (furin DENV) in a 1:3:1 ratio of replicon, CprME, and furin by mass. In 
order to generate RVP populations that retained significant levels of uncleaved prM (FI-
DENV), medium from transfected cells was exchanged with medium supplemented with 
50 µM furin inhibitor (FI) Dec-RVKR-CMK at four hours post-transfection (Enzo Life 
Sciences, Farmingdale, NY).  
 
The efficiency of prM cleavage in RVP preparations was determined by Western blotting 
as previously described (32, 315). Briefly, DENV RVPs were partially purified over a 




containing 1% Trition, 100 mM Tris, 2 M NaCl, and 100 mM EDTA. The protein content 
of lysates was analyzed using E- and prM-reactive mAbs (4G2 and GTX128093 
(Genetex), respectively) at 1 µg/ml. The efficiency of prM cleavage was evaluated on 
blots normalized by loading equivalent E protein. 
 
4.3.7 Measuring the infectious titer of DENV RVPs. 
The infectious titer of each RVP stock was determined using Raji cells that express the 
flavivirus attachment factor DCSIGNR as described previously (130, 259, 316). Cells 
were infected with serial two-fold dilutions of transfection supernatant, incubated at 37°C 
for two days, and then scored for GFP expression by flow cytometry. Only data from the 
linear portion of the virus dose-infectivity curves were used to compare RVP titers. 
Infectious titer was calculated using the formula: IU/sample volume = (percent GFP 
positive cells) x (number of cells) x (dilution factor). 
 
4.3.8 DENV neutralization assays. 
DENV RVP stocks were diluted and incubated with serial dilutions of mAb or serum for 
one hour at room temperature prior to the addition of Raji-DCSIGNR cells, unless 
specified otherwise. Infections were carried out at 37°C for 48 hours and infectivity was 
scored as the fraction of GFP-expressing cells determined using flow cytometry. 
Antibody-dose response curves were analyzed using non-linear regression analysis (with 




concentration of antibody (EC50) or serum dilution (NT50) required to reduce infection 
by half.  
 
4.3.9 Statistical analysis. 
Statistical analyses were performed using Prism software (GraphPad). Log EC50 or Log 
NT50 values were compared using Student’s t-test when comparing two samples. For 
comparisons of more than two samples, Log NT50 values were compared by one-way 
ANOVA followed by Tukey’s multiple comparisons test or, where indicated, Šidák 
correction for multiple comparisons.  
 
4.4 Results 
4.4.1 Strategy for identifying epitopes recognized by type-specific antibodies elicited 
by DENV1 vaccination. 
The goal of this study was to identify epitopes recognized by DENV1 TS-neutralizing 
antibodies elicited by vaccination. Our analyses employed immune sera collected during 
the clinical evaluation of individual components of the NIAID tetravalent vaccine 
candidate (reviewed by (13)). The attenuated DENV1 in this vaccine (rDEN1Δ30) is 
derived from the South Pacific genotype 4 Western Pacific (WP) strain (14). The DENV2 
component of the tetravalent formulation (rDEN2/4Δ30(ME)) is the Southeast Asian 
genotype 2 New Guinea C strain (NGC) (15). The envelope proteins of these viruses 
differ by 158 amino acids (Figure 4.1A and 4.1B); 68 amino acids that differ between 




DENV virion (Figure 4.1C, see Materials and Methods) (313). Both rDEN1Δ30 and 
rDEN2/4Δ30(ME) vaccines were tested as monovalent formulations in phase I clinical 
studies in humans (317, 318). To identify amino acids recognized by TS-neutralizing 
antibodies, we created a panel of DENV1 variants to replace surface-accessible residues 
on the mature DENV1 virion with those found on DENV2 NGC (detailed below). This 
panel of mutants was then screened using pooled immune sera collected during 
monovalent DENV1 and DENV2 vaccine studies for those exhibiting reduced sensitivity 
to neutralization by DENV1, but not DENV2, immune sera.  
 
Construction and functional characterization of libraries of DENV1 E protein variants 
were performed using DENV reporter virus particles (RVPs). RVPs are produced by 
complementation of a self-replicating sub-genomic flavivirus replicon with a plasmid 
encoding viral structural genes. These virus particles are capable of only a single round of 
infection and allow virus entry to be scored as a function of reporter gene expression. 
Flavivirus RVPs have been used extensively to study the functional properties of anti-
flavivirus antibodies (32, 130, 171, 199, 260, 319). This technology allows for the rapid 
generation of structural gene variants by exchanging the plasmids used in 
complementation studies, simplifying the construction and characterization of a large 
library of DENV1 mutants. Furthermore, because the RVPs are not passaged in cell 








Figure 4.1 Surface-accessible residues that differ between DENV1 and DENV2 identified for 
mutagenesis. The flavivirus E protein contains three distinct domains (DI-III) and forms antiparallel 
dimers on the mature virus particle. Shown is the crystal structure of the soluble ectodomain of the DENV2 
E protein dimer (PDB 1OAN) as viewed from the top (top panels) and side (bottom panels). (A) Ribbon 
diagram of the E protein with DI, II, and III colored in red, yellow, and blue, respectively (311). (B) The 
130 amino acid residues in the soluble ectodomain that differ between the DENV1 and DENV2 
components of the NIAID candidate tetravalent vaccine are highlighted in blue on one E protein; the 
second E protein of the dimer is shaded in green. (C) Surface accessibility was estimated using solvent 
accessible surface areas of the residues determined from the crystal structure (UCSF Chimera package), 
with a cut-off value of 30 Å2 (312). Residues selected for study were restricted to the top of the dimer. The 
68 residues identified as surface-accessible differences between DENV1 WP and DENV2 NGC are shown 
in red.  
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Immune sera used to characterize and screen DENV1 mutant libraries were pooled from 
recipients of DENV1 or DENV2 vaccine candidates (two and three vaccine recipients, 
respectively) (317, 318). The neutralization titer (NT50) of antibodies in these pooled 
serum samples was determined using wild type (WT) DENV1 WP and DENV2 NGC 
RVPs. As expected, antibodies present in the DENV1 immune sera efficiently neutralized 
DENV1 RVPs (Log NT50 2.67±0.04, n=11) (Figure 4.2A and 4.2B). Cross-reactive 
neutralizing antibodies in the sera, measured using DENV2 RVPs (Log NT50 1.32±0.05, 
n=11), were significantly less potent when compared to DENV1 neutralization (23-fold; 
p<0.0001). A similar pattern of TS- and CR- neutralization was observed in reciprocal 
studies with DENV2 immune sera (Figure 4.2C and 4.2D), which neutralized DENV2 
RVPs (Log NT50 3.06±0.03, n=11) at significantly greater dilutions than DENV1 RVPs 
(Log NT50 1.80±0.04, n=9) (20-fold, p<0.0001). 
 
4.4.2 Construction of a library of DENV1 variants with individual substitutions to 
match DENV2 at surface-accessible differences. 
To disrupt TS epitopes recognized by DENV1 immune sera, we created a library of 
RVPs in which the 68 surface-accessible residues that vary between the DENV1 and 
DENV2 components of the vaccine (Figure 4.1) were used to guide construction of a 
panel of 54 DENV1 variants containing only one, two, or three substitutions each; in 
cases where adjacent residues were selected for mutagenesis they were introduced into 
the same RVP. All 54 DENV1 variants were infectious, albeit to differing degrees (n=2-





Figure 4.2 Type-specific neutralization by DENV immune sera from a clinical vaccine trial. Pooled 
immune sera from a DENV1 or DENV2 vaccine study were tested for their capacity to neutralize DENV1 
and DENV2 RVPs. Sera pooled from multiple vaccinees (two and three for DENV1 and DENV2, 
respectively) were used in neutralization experiments by incubating RVPs with serial dilutions of immune 
sera for one hour at room temperature, before addition to Raji-DCSIGNR cells. After incubation at 37°C 
for two days, infection was measured using flow cytometry. Dose response curves for (A) DENV1 sera and 
(C) DENV2 sera are expressed relative to the infectivity of the RVPs in the absence of serum. The 
concentration of sera indicated on the x-axis is expressed as Log10 (dilution factor of serum). Error bars 
represent the standard error of duplicate infections. Dose response curves shown in (A) and (C) are 
representative of 11 and nine independent experiments, respectively, performed using at least three 
independent RVP preparations. Neutralization titer (NT50) values were determined by nonlinear regression 
analysis using Prism software (GraphPad), and are summarized for (B) DENV1 sera and (D) DENV2 sera. 
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Figure 4.3 Infectivity of DENV1 E protein variants. A panel of 54 DENV1 RVP variants containing 
single, double, or triple amino acid changes was constructed by site-directed mutagenesis. This panel 
represented all surface-accessible residues identified in Figure 4.1C. The infectious RVP titer for each 
variant was determined concurrently with WT DENV1 using Raji-DCSIGNR cells. Values are the mean 
relative titer as compared to WT DENV1 infectivity measured in parallel from at least two independent 
RVP preparations; error bars represent standard error of the mean. Variants located in domains I, II and III 



























































































































































































































immune sera was tested, and three patterns emerged. The majority of DENV1 variants 
(81%) were neutralized to the same extent as WT DENV1 tested in pairwise experiments 
(Figure 4.4A and D). Eight variants in this panel (15%) revealed a small (1.5- to 2-fold) 
but reproducible increase in sensitivity to neutralization (Figure 4.4B and D). These 
variants were also typically more sensitive to neutralization by the DII-fusion loop 
reactive mAb E60 (Figure 4.5). Mechanisms with the potential to increase neutralization 
sensitivity in this context are discussed below. Finally, two mutants, E126K and E157K, 
exhibited a statistically significant decrease in sensitivity to neutralization by pooled 
DENV1 sera (3.5-fold (n=10, p<0.0001) and 2.4-fold (n=10, p<0.0001), respectively) 
(Figure 4.4C and 4.4D). Neither of these two mutations conferred an altered sensitivity 
to neutralization by mAb E60 (Figure 4.5).  
 
To investigate whether a single DENV1 variant encoding both E126K and E157K 
mutations had an even further reduction in neutralization sensitivity, we combined them 
into a single construct (Figure 4.6A). RVPs produced using this DENV1 E126K/E157K 
variant were able to infect cells, albeit with greatly reduced titer as compared to WT 
DENV1 RVPs (>1,000 fold, p<0.001 for all time points, n=2-4) (Figure 4.6B). 
Neutralization studies using single and double mutants revealed the DENV1 
E126K/E157K variant was more resistant to neutralization by DENV1 immune sera than 
either single mutant (Log NT50 1.79±0.06, n=11) (p<0.0001 for both comparisons) 






Figure 4.4 Impact of mutations on the neutralization potency of DENV1 immune serum. The 
sensitivity of the 54 DENV1 variants to neutralization by DENV1 immune serum was compared to WT 
DENV1. (A-C) Examples of the three patterns of neutralization by DENV1 immune sera observed are 
shown. Error bars represent the standard error of duplicate infections. (D) Neutralization sensitivities of all 
DENV1 variants to DENV1 immune sera are depicted as the mean fold increase in neutralization 
sensitivity ([NT50 variant]/[NT50 WT]); error bars represent standard error of the mean of 2-5 independent 






























































































































































































































































































































Figure 4.5 Sensitivity of DENV1 variants to neutralization by mAb E60. Each member of the panel of 
54 DENV1 variants was tested in parallel with WT DENV1 for sensitivity to neutralization by CR mAb 
E60. Dose response curves were generated by incubating serial dilutions of antibody with RVPs for one 
hour at room temperature, before addition of Raji-DCSIGNR cells. EC50 values for each curve were 
determined by nonlinear regression analysis using Prism software (GraphPad), and are depicted as the fold-
change in neutralization sensitivity from WT DENV1 ([EC50 WT]/[EC50 variant]). The experiment was 
repeated for a subset of the panel to capture the variability of the assay; error bars, when present, represent 


























































































































































































































































Figure 4.6 Combined effect of DENV1 mutations E126K/E157K on the neutralization potency of 
DENV1 immune serum. (A) The location of residues E126 and E157 are highlighted on the E protein 
crystal structure as cyan and green spheres, respectively. E protein domains are colored as in Figure 1. (B) 
Infectious titer of DENV1 E126K/E157K RVPs harvested at four time points post-transfection was 
determined in parallel studies with WT DENV1 using Raji-DCSIGNR cells; error bars represent the 
standard error of the mean of 2-4 independent experiments. (C and D) DENV1 E126K/E157K RVPs were 
tested for sensitivity to neutralization by the DENV1 immune serum. (C) Representative dose-response 
curves for the single and double mutants are shown; error bars represent the standard error of duplicate 
infections. (D) The neutralization sensitivity is summarized as the fold-increase in NT50 from WT DENV1 
for the single mutants E126K and E157K (n=10), the E126K/E157K double mutant (n=11), and DENV2 
(n=11); error bars represent the standard error of the mean. ***p<0.0001 for a comparison of the Log NT50 






























































































4.4.3 Characterization of the E126K/E157K DENV1 variant. 
Our screening data with pooled immune sera suggested antibodies that bound epitopes 
containing residues E126 and E157 were a functionally significant component of the 
polyclonal antibody response to DENV1 vaccination. To validate this interpretation, we 
performed control experiments to address aspects of flavivirus biology with the potential 
to reduce the apparent sensitivity of flaviviruses to antibody-mediated neutralization.  
 
First, we conducted experiments to demonstrate that the reduced sensitivity of the 
E126K/E157K variant to neutralization was not an artifact of its low titer and/or an 
overall disruption of the antigenic surface of the virion. An assumption of quantitative 
neutralization studies is that the observed neutralizing activity is dependent solely on the 
concentration of antibody and its affinity/avidity for viral antigens; the results of 
neutralization studies should be independent of the amount of antigen/virus in the 
experiment (320, 321). Excess antigen in virus preparations (due to a reduced specific 
infectivity) may shift antibody dose-response curves towards higher concentrations of 
antibody if present in sufficient amounts to reduce the concentration of free antibody in 
solution (260). To rule out the confounding effects of excess antigen in preparations of 
the E126K/E157K variant, we performed control studies using TS-neutralizing mAbs that 
have been mapped to the DIII lateral ridge (47). Neutralization by these mAbs should not 
be affected by the DI/DII mutations. Both mAb DENV1-E103 (Figure 4.7A, n=8) and 
mAb DENV1-E105 (Figure 4.7B, n=5) neutralized WT DENV1 and DENV1 
E126K/E157K RVPs to an equivalent extent (p= 0.14 and 0.57, respectively). 





Figure 4.7 Neutralization of DENV1 E126K/E157K by DENV1 mAbs. WT DENV1 and DENV1 
E126K/E157K RVPs were evaluated for sensitivity to neutralization by DENV1 DIII-binding mAbs. (A 
and B) Within each panel, representative dose response curves for each antibody are shown on the left; 
error bars represent the standard error of duplicate infections. Plots on the right show the EC50 values 
obtained from independent experiments; error bars represent standard error of the mean. The antibodies 
tested were (A) mAb E103 (n=8, p=0.14), and (B) mAb E105 (n=5, p=0.57). (C-H) WT DENV1 and 
DENV1 E126K/E157K RVPs were evaluated for sensitivity to neutralization by six additional DENV1 
mAbs that bind diverse epitopes on DIII (47). The mAbs used were (C) E90 (N-terminal region and BC-
loop); (D) E98 (F- and G-strands); (E) E99 (A-strand); (F) E100 (A-strand, BC and DE loops); (G) E102 
(N-terminal region and the BC loop); and (H) E106 (A-strand, BC, DE, and FG loops). Dose response 
curves shown are representative of two independent experiments; error bars represent the standard error of 
duplicate infections. EC50 values for WT and the variant were less than 2-fold different in all cases. 
















































































































































































































 instance we observed less than a two-fold difference in the EC50 of WT and the 
E126K/E157K variant (Figure 4.7C-H, n=2). Altogether, these results demonstrate that 
studies of the neutralization sensitivity of the DENV1 E126K/E157K variant are not 
confounded by excess antigen arising from a reduction in the specific infectivity of the 
virus.  
 
We have shown previously that changes in the efficiency of virion maturation can 
markedly impact the sensitivity of flaviviruses to neutralization by antibodies (32). 
Because mutations in the E protein have the potential to impact the efficiency of prM 
cleavage, we investigated the maturation state of the DENV1 E126K/E157K variant 
using biochemical and functional approaches. The prM content of the DENV1 
E126K/E157K variant was found to be similar to WT by Western blot (Figure 4.8A). 
The DII-FL-reactive mAb E60 neutralizes flaviviruses in a maturation state-dependent 
fashion and serves as a sensitive functional probe for changes in virion structure that 
expose this otherwise cryptic epitope on the mature virion (32, 138). Manipulating the 
efficiency of prM cleavage modulates the potency of E60 against DENV1 WP; increasing 
the efficiency of virion maturation reduces sensitivity of the virion to neutralization 
(Figure 4.8B). That no significant difference in the potency of E60 was observed when 
studying WT DENV1 (EC50=1.3x10-9±2x10-10M, n=8) and DENV1 E126K/E157K 
(EC50=1.9x10-9±5x10-10M, n=8) (p=0.68) (Figure 4.8C) suggests the efficiency of virion 
maturation of WT and the E126K/E157K variant are similar on infectious viruses. 
Finally, using RVP populations in which the efficiency of prM cleavage was greatly 




Figure 4.8 Characterization of the E126K/E157K DENV1 variant. (A) WT DENV1 and E126K/E157K 
RVPs were analyzed by Western blot with an anti-E mAb and an anti-prM mAb. The efficiency of prM 
cleavage was evaluated on blots normalized by loading equivalent E protein. (B) WT DENV1 RVPs were 
produced using standard methods (Std), in the presence of high levels of human furin expression (furin), or 
in cells treated with furin inhibitor (FI) and then tested for sensitivity to neutralization by mAb E60. Three 
independent experiments were performed; representative dose response curves are shown. Error bars 
represent the standard error of duplicate infections. (C) DENV1 E126K/E157K was evaluated for 
sensitivity to neutralization by mAb E60 as compared to WT DENV1. Representative dose response curves 
are shown on the left; error bars represent the standard error of duplicate infections. EC50 values from 
independent experiments are shown in the right panel; error bars represent standard error of the mean (n=8, 
p=0.68). (F) Furin- and FI-DENV1 RVPs were tested for sensitivity to neutralization by sera from DENV1 
vaccine recipients. Error bars represent standard error from three independent experiments. Statistical 
evaluation using ANOVA followed by a Šidák correction for multiple comparisons failed to identify a 
difference between Furin- and FI-DENV1 RVPs (p>0.05 for each pair). (G) DENV1 E126K/E157K was 
evaluated for sensitivity to neutralization by pooled sera from DENV2 vaccine recipients. A representative 
dose response curve is shown on the left; error bars represent the standard error of duplicate infections. 
NT50 values obtained from eight independent experiments are shown on the right; error bars represent 













































































































































and DENV1 immune sera from eight vaccine recipients, we established that the TS-
neutralizing activity in these sera was not markedly sensitive to the maturation state of 
the virus particle (Figure 4.8D). In each instance, furin- and FI-RVPs were neutralized 
equivalently. Altogether our data strongly suggest that the reduction in sensitivity of the 
DENV1 E126K/E157K variant to neutralization by TS antibodies present in vaccine 
immune sera is not an artifact of a change in the efficiency of virion maturation.  
 
The accessibility of antibody epitopes on the virion may also be modulated by changes in 
the structure of the virion as it samples multiple conformations at equilibrium (known as 
viral “breathing”) (138, 173, 175, 322, 323). The impact of viral dynamics on antibody-
mediated neutralization is most readily observed with antibodies that bind epitopes 
predicted to be poorly exposed on the surface of the mature virion. The neutralization 
potency of E60 is also sensitive to viral structural dynamics (138). That E60 neutralized 
both WT and the DENV1 E126K/E157K variant with equivalent efficiency (Figure 
4.8C) indicates that the reduced sensitivity of this variant to neutralization by DENV1 
immune sera is not a result of a change in the extent of viral “breathing”.  
 
Finally, studies with pooled DENV2 immune sera revealed these mutations only altered 
sensitivity to TS antibodies and not CR antibodies. The sensitivity of DENV1 
E126K/E157K RVPs to neutralization by cross-reactive DENV2 immune sera was 
similar to WT DENV1 RVPs (1.3-fold, n=8, p=0.08) (Figure 4.8E). Together, these 
experiments support the conclusion that mutation at residues E126K and E157K 




Furthermore, the reduced sensitivity of variant E126K/E157K to immune sera from 
DENV1, but not DENV2, vaccinated individuals was not an artifact of changes in the 
structural dynamics of the virion, the efficiency of virion maturation, gross changes in the 
antigenic structure of the virion, or antigen excess in the neutralization assay. 
 
4.4.4 Prevalence of an epitope recognized by TS antibodies present in the immune 
sera of DENV1-vaccinated subjects. 
E126 and E157, we next performed longitudinal and cross-sectional studies of immune 
sera obtained from individual recipients of a DENV1 live-attenuated vaccine candidate 
(310). Participants in this vaccine study were administered vaccine on days 0 and 180, as 
described previously (310). Neutralization studies with sera from three subjects collected 
at days 28, 42, 180, 208, and 222 post-vaccination were performed using WT DENV1, 
WT DENV2, and DENV1 E126K/E157K RVPs. These three subjects were selected for 
study because they represented both high and low neutralizing antibody responses among 
participants in the phase I study. Dose response curves and summary NT50 values of sera 
from longitudinally tested subjects are shown in Figure 4.9. As anticipated, sera from 
post-vaccination samples neutralized DENV1 more efficiently than DENV2. In each 
instance, neutralization activity declined over time and was not boosted significantly by a 
second dose of vaccine, consistent with previous reports (Figures 4.9 and 4.10) (310). 
 
Longitudinal analysis revealed that the sensitivity of the E126K/E157K variant to 
neutralization by DENV1-immune sera varied with time and among the three subjects 






Figure 4.9 Longitudinal analysis of the effects of DENV1 E126K/E157K mutations on serum 
neutralizing activity. Sera collected from three DENV1 vaccine recipients at five times post-vaccination 
were tested for a capacity to neutralize WT DENV1, DENV2, and DENV1 E126K/E157K RVPs. (A) 
Dose-response curves for immune sera from one subject are shown. Error bars represent the standard error 
of duplicate infections. (B) NT50 values for each curve were determined by nonlinear regression analysis 









































































































































Figure 4.10 Cross-sectional analysis of the contribution of the E126K/E157K epitopes on TS-
neutralization. Sera from an additional 21 DENV1 vaccine recipients collected on days 42 and 222 (when 
available) were tested for their capacity to neutralize WT DENV1, DENV2 and DENV1 variant 
E126K/E157K RVPs. (A) The mean neutralization potency (Log NT50) of the sera against each virus is 
shown; error bars represent one standard deviation of the mean. ***p<0.0001; ns, p=0.15. (B) The 
neutralization titers (NT50) of the sera against WT DENV1, DENV2 and DENV1 E126K/E157K RVPs are 
presented. The fold-difference in sensitivity between DENV1 variant E126K/E157K RVPs and DENV2 
RVPs was determined by the equation (NT50 DENV1 E126K/E157K)/(NT50 DENV2). Red shading 
indicates a <3 fold difference, yellow shading corresponds to a 3-6 fold difference, and green shading 











































E126 and E157 increased with time post-vaccination. By day 222, DENV2 and DENV1 
E126K/E157K RVPs were neutralized to an equivalent degree (Figure 4.9A and 4.9B). 
The reduced sensitivity of DENV1 E126K/E157K RVPs to neutralization was observed 
at earlier time points in the sera of Subject 57, suggesting the TS-antibody response in 
this individual was focused early on epitopes impacted by mutating these two residues 
(Figure 4.9B). In contrast, while the sensitivity of DENV1 E126K/E157K RVPs to 
neutralization was reduced in comparison to WT at all time points sampled from Subject 
39 (from 2-6 fold), mutation of these two residues alone did not ablate the entire TS 
response (Figure 4.9B).  
 
To better understand the contribution of epitopes defined by the E126K and E157K 
mutations in the TS response to the DENV1Δ30 vaccine in a larger sample set, we 
assayed sera collected from an additional 21 DENV1 vaccine recipients at two time 
points post-vaccination (day 42 and 222; day 222 was collected 42 days after the second 
vaccine dose was administered). Antibody dose-response curves were generated for each 
sample using WT DENV1, WT DENV2, and DENV1 E126K/E157K RVPs as described 
above. The NT50 values calculated from this cross-sectional study are presented in 
Figure 4.10A and B. As expected, vaccine sera most efficiently neutralized DENV1; 
DENV1 E126K/E157K and DENV2 RVPs were significantly less sensitive to 
neutralization at both time points studied (p<0.0001 for both comparisons) (Figure 
4.10A). While comparisons of the neutralization titer against DENV1 E126K/E157K and 
DENV2 revealed differences at day 42 post-vaccination (p<0.0001), by day 222 no 





On average, we observed a 3.5-fold decrease in neutralization titers measured with 
DENV1 RVPs between day 42 and day 222 post-vaccination. This decay was more rapid 
than the change in DENV2-reactive titers measured at these two time points (mean 2.4-
fold decrease) (p<0.01). Of interest, the ability of DENV1 sera to neutralize the 
E126K/E157K variant reactive antibody declined most dramatically between days 42 and 
222 (a mean 4.8-fold decrease). This decline in sensitivity to neutralization was more 
rapid that that observed with either DENV1 (p<0.05) or DENV2 (p<0.0001) RVPs. This 
data is in agreement with our interpretation that over time, antibodies in DENV1-immune 
sera become more focused on epitopes containing residues E126 and E157. On average, 
RVPs containing mutations at these positions become more difficult to neutralize with 
time post-vaccination.  
 
Analysis of individual neutralization titers revealed the same pattern (Figure 4.10B). On 
day 42, the serum of roughly half the recipients neutralized DENV1 E126K/E157K RVPs 
less efficiently than WT DENV1 RVPs. The contribution of antibodies binding epitopes 
impacted by mutation of E126 and E157 was monitored as the difference in 
neutralization sensitivity of the DENV1 E126K/E157K mutant and DENV2 RVPs 
(highlighted in red, yellow, and green to indicate 0-3, 3-6, and >6 fold differences in 
NT50). In 46% of the day 42 samples tested, the neutralization titer of the E126K/E157K 
variant was found to be within 3-fold of the cross-reactive DENV2 neutralization titer 
(Figure 4.10B). By day 222 post-vaccination, 77% of the NT50 values obtained with the 




the trend observed in the longitudinal analysis described above. Together, these data 
identify a significant functional contribution of epitopes containing residues E126 and 
E157 in the TS DENV1 response that increases with time.  
 
4.5 Discussion 
Interpreting the serology of flaviviruses is hindered by extensive cross-reactivity and 
significant differences in the functional properties of antibodies that bind different 
epitopes on the virion (47, 48, 50-54). Several approaches have been employed to 
deconstruct the complexity of the polyclonal antibody response to DENV. Biochemical 
studies using recombinant proteins or subviral particles have identified mutations in the E 
protein that reduce recognition by antibodies in DENV immune sera in an ELISA or 
Western blot assay format (54, 324, 325). A limitation of this type of approach is that it 
does not account for the marked difference in neutralization potential among antibodies 
of varying specificity. A neutralization response driven by the contribution of a low 
concentration of potent neutralizing antibodies may be difficult to detect using 
biochemical studies.  
 
The antibody repertoire elicited by DENV infection or vaccination has also been 
investigated using approaches that allow study of the functional properties of antibodies 
in immune sera. Exciting advances have been made towards understanding the DENV 
antibody repertoire through the analysis of the specificity of human mAbs (50, 59, 60). A 
strength of this approach is that it enables functional analysis of antibody specificities 




of DENV-reactive memory B-lymphocytes, it is unknown how faithfully these methods 
capture the breadth of the polyclonal humoral immune response in vivo, and how 
screening bias impacts the mAbs selected for study. A recent study of 26 DENV-reactive 
human mAbs obtained from subjects immunized with the rDEN1Δ30 vaccine candidate 
studied herein identified only three mAbs that neutralize DENV (301). The functional 
specificity of the polyclonal DENV immune response has also been investigated by 
depletion of immune sera using recombinant proteins. These studies suggested antibodies 
that bind E-DIII are not a significant component of the neutralizing antibody response 
and play only a modest role in protection in the AG129 mouse model of DENV 
infection/disease (197, 326). This finding was confirmed using infectious clones 
encoding mutations in E-DIII (327).  
 
The number of epitopes that contribute to the neutralizing activity of the polyclonal 
antibody response to DENV remains unknown. To date, insight into where neutralizing 
antibodies present in human sera bind DENV has been limited principally to negative 
data. The goal of the present study was to identify the epitopes recognized by neutralizing 
antibodies of the type-specific DENV1 response following vaccination. We undertook a 
mutagenesis approach to identify amino acid substitutions that conferred a reduction in 
sensitivity to neutralization by DENV1 immune sera, but not cross-reactive antibodies 
present in DENV2 sera. We created a library of DENV1 RVPs encoding mutations at 
residues predicted to be surface-accessible on the mature virion that differ between 




that when mutated together abrogated a large portion of the TS-neutralizing antibody 
response in 77% of vaccinated subjects.  
 
That two amino acid substitutions were sufficient to significantly reduce the TS-antibody 
response in the majority of vaccinees was a surprise. These data suggest the TS-antibody 
response is remarkably focused. Similar conclusions were reached in studies of the 
complexity of the polyclonal antibody response to HIV-1 and influenza (328-331). 
Residues E126 and E157 are very conserved among DENV1 viruses; the mutations 
identified in our study were found only once (E126K) or not at all (E157K) among 1,398 
DENV1 sequences available for in silico analysis (332). Thus, the ability of DENV1 to 
escape from neutralization by mutation may be limited by the functional pressure of 
cross-reactive antibody and a substantial fitness cost. A more detailed analysis of the 
functional consequences of mutations at these residues is underway. 
While the TS-immune response of a majority of volunteers in our study was focused 
significantly on epitopes affected by mutations at E126 and E157, these changes had a 
somewhat reduced impact on the potency of immune sera from five volunteers. This 
suggests that additional residues are involved in the fine specificity of the response and 
will require further study. Limited secondary screening with a subset of the panel of 
DENV1 variants identified residue 203 as a significant contributor to TS-neutralization 
patterns of Subject 38 (Figure 4.11), but not the others. As this residue is located within 
13 Å from residue 126, it is possible that mutations at this position impact recognition of 






Figure 4.11 Neutralization of additional DENV1 variants by sera from DENV1 vaccine recipients. 
While the TS-immune response of a majority of volunteers in our study was focused significantly on 
epitopes affected by mutations at E126 and E157, these changes had a reduced impact on the potency of 
immune sera from five volunteers (Subjects 36, 38, 39, 40, and 45). Secondary screening of day 222 sera 
from these subjects was performed with a panel of ten of DENV1 variants shown to modestly decrease the 
potency of the DENV1 pooled serum (Figure 4.4). Only a role for mutant K203N in modulating the 
neutralization sensitivity of DENV1 immune sera of Subject 38 was identified as significant using our 
screening metric (<3-fold difference in NT50 between variant K203N and DENV2, n=2). Antibody-dose 


























































































































































While, to our knowledge, residues 126 and 157 on DENV1 E protein have not yet been 
identified in neutralization escape studies with DENV mAbs, recent studies have 
identified a complex epitope in proximity to E157. Studies of the human anti-WNV mAb 
CR4354 identified an epitope at the junction of E-DI and E-DII that exists only on the 
intact virion, and not on soluble E protein (145). Four human mAbs have since been 
characterized that bind in the same region. The footprint of the TS DENV1 mAb DENV 
HM14c10 has been solved using cryo-electron microscopy reconstruction and has 
confirmed the discontinuous structure of the epitope and its similarity to CR4354 (58, 
300). Neutralization escape mutants have been identified for HM14c10 as well as three 
additional human mAbs thought to recognize quaternary epitopes on DENV; each escape 
variant was mutated around the DI-II hinge region and within the CR4354 footprint (57, 
300). The E157K mutation identified in our study is close to the hinge region. However, 
it remains unclear if antibodies that bind DENV1 at this location engage a quaternary 
epitope similar to CR4354, as this residue falls just outside the DI-DII hinge epitopes 
defined by the footprints of WNV CR4354 or DENV HM14c10. Furthermore, the 12 
surface-exposed residues that differ between DENV1 and DENV2 present in the 
published DI-DII hinge epitope footprints did not themselves markedly reduce sensitivity 
to neutralization by DENV1 sera in this screen.  
 
The dense arrangement of E proteins on the virion complicates our understanding of 
antibody recognition. Many well-characterized epitopes are not predicted to be accessible 
for antibody binding using existing static models of the mature DENV structure (54, 140, 




of the CR repertoire produced by mouse and human following flavivirus infection, yet 
bind an epitope not predicted to be accessible for antibody recognition (54). The 
accessibility of cryptic epitopes like the DII-FL has been shown to be governed by 
several factors (32, 138). Viruses exist as an ensemble of structures at equilibrium 
(reviewed by (322, 333)). “Breathing” of envelope proteins incorporated into the 
flavivirus virion has been shown to alter epitope accessibility and sensitivity to 
neutralization by monoclonal and polyclonal antibody (138, 173, 334). In addition, many 
antibodies are sensitive to the maturation state of the virus particle (32). Engineered 
mutations or naturally occurring variation have the potential to alter the heterogeneity or 
dynamics of the virion, and therefore may impact epitope exposure. While we have 
identified amino acids that contribute to the type-specific recognition of the DENV1 
Western Pacific strain, epitopes containing these amino acids may play a reduced or 
enhanced role in the context of other viral E protein sequences. Of interest, ~30% of the 
vaccine recipients studied within neutralize a related DENV1 strain 16007 more 
efficiently than the WP strain used in the DENV1 vaccine candidate (data not shown). 
This enhanced recognition may reflect differences in the “breathing” of these two viruses 
that alter the accessibility of epitopes on the virus particle, as suggested in a recent study 
(172). As our analysis was focused on surface accessible differences between the DENV1 
and DENV2 components of the vaccine, it is possible that amino acid variation among 
DENV1 strains and differences in the extent of “viral breathing” (and therefore epitope 
exposure) will impact the pattern of type-specific recognition of different DENV1 strains. 
It remains to be determined whether the two resides characterized within will be useful as 




Evaluating the contribution of this structural complexity towards neutralization 
sensitivity is a critical component of understanding the antigenic surface of flaviviruses 
and how this varies among strains within and between serotypes.  
 
The identification of major targets of the TS-neutralizing antibody response to DENV1 
vaccination represents an important step toward a more complete understanding of the 
humoral immune response to DENV. Whether epitopes including residues E126 and 
E157 contribute significantly to the neutralizing antibody response to natural infection or 
vaccination with all four DENV serotypes remains to be determined. The four serotypes 
of DENV share a 63% or greater amino acid identity and presumably the same overall 
virion structure. The epitopes engaged by TS-neutralizing antibodies elicited by infection 
of other DENV serotypes are unknown. Of note, the introduction of the reciprocal 
mutations at positions K126 and K157 of DENV2 NGC did not markedly shift the 
neutralization curve of DENV2 immune sera obtained from vaccine recipients (Figure 
4.12). These data suggest that antibodies that contribute to the TS-neutralizing antibody 
response may bind distinct epitopes on all four DENV serotypes. Beyond the 
identification of significant epitopes in DENV, the data and experimental approaches 
described within provide insight into mutagenesis approaches for deconstructing the 
functional components of the polyclonal DENV antibody response and will be used to 
guide future studies on the functionally important epitopes involved in the neutralization 





Figure 4.12 Effect of mutations at residues 126 and 157 on DENV2 RVPs. To test whether the residues 
126 and 157 are targets of TS antibodies in DENV2 sera, a DENV2 NGC variant was constructed 
containing the reciprocal mutations, K126E and K157E. (A) DENV2 K126E/K157E RVPs were tested for 
sensitivity to neutralization by pooled DENV2 sera. Representative dose-response curves are shown on the 
left; error bars represent the standard error of duplicate infections. NT50 values from four independent 
experiments are shown on the right and reveal a modest 1.5-fold increase in neutralization sensitivity of the 
variant (p<0.05). (B) DENV2 K126E/K157E was tested for sensitivity to neutralization by CR mAb E60. 
Representative dose-response curves are shown on the left; error bars represent the standard error of 
duplicate infections. NT50 values from four independent experiments are shown on the right, and reveal a 
similar 1.4-fold increase in sensitivity to neutralization compared to WT DENV2, though this difference 




















































































Chapter 5: Investigating antigenic differences between DENV1 
strains that mediate recognition by antibodies in polyclonal sera. 
 
 
5.1 Introduction  
Phylogenetic analyses reveal that within each DENV serotype, strains additionally cluster 
into three to five distinct groups, or genotypes (335). Strains within a genotype exhibit 
less than 6% nucleotide sequence or 3% amino acid sequence variation in the E gene 
(74). DENV serotype 1 is divided into five genotypes that differ by up to 6-10% in their 
E gene (nucleotide) sequences and up to 4-5% in their E protein (amino acid) sequences 
(335-337). Despite the sequence diversity between genotypes, it has generally been 
accepted that following primary infection, immunity develops against all of the strains of 
the infecting serotype. However, DENV genotype- and strain- dependent differences in 
neutralization sensitivity have recently become a focus of investigation, and both 
monoclonal antibodies (mAbs) and polyclonal sera have been characterized that have 
genotype-specific differences in neutralization potency (47, 48, 172, 178, 216, 307, 338).  
 
Genotype- or strain-dependent differences in an antibody’s neutralization potency may be 
due to sequence variation that occurs within the antibody’s binding footprint and affects 
the binding energetics between the antibody and its epitope (47, 172, 178, 216, 307). 
Alternatively, differences in potency may be unrelated to a change in binding energetics 
(339, 340). Rather, amino acid variation that occurs outside of an epitope can indirectly 




have an effect on flavivirus epitope exposure are virion maturation state and viral 
structural dynamics (32, 138). While virion maturation state has been shown to modulate 
the potency of many mAbs and cross-reactive polyclonal antibodies (pAbs) in DENV 
sera (32-34, 226), it’s impact on the potency of the type-specific, neutralizing antibody 
response to DENV is minimal (33, 261).  
 
Virion structural dynamics or viral “breathing” can affect flavivirus epitope exposure by 
altering the structural conformations sampled by dynamic E proteins (138). While the 
impact of virion structural dynamics on the potency of the human polyclonal antibody 
response to DENV is not known, viral breathing has been shown to impact the potency of 
some mAbs in a strain-dependent manner (47, 172, 178). For example, a study 
characterizing a panel of DENV1 mAbs found a marked reduction in neutralization 
potency against DENV1 strain WP compared to DENV1 strain 16007 for mAb E111 
(47). Sequence variation within the E111 epitope on DIII did not fully explain the 
difference in neutralization sensitivity. Domain III of strains WP and 16007 differ by 
only two amino acids, at residues that did not match with the mAb epitope-mapping data. 
Notably, structural analysis of E111 revealed that its epitope was not predicted to be 
accessible to antibody binding on the cryo-EM reconstruction of DENV (172). Further 
experiments with E111 revealed that its neutralization potency increased with time and 
temperature of incubation of the immune complexes prior to addition to cells; this is 
consistent with previous studies demonstrating that cryptic epitopes may become 
available for antibody recognition in a time- and temperature-dependent fashion due to 




increase in sensitivity to E111 neutralization was strikingly strain-dependent (172). 
Neutralization of WP was greatly enhanced by the increased incubation times and 
temperatures, while strain 16007 had more modest increases in sensitivity, presumably 
because the epitope was available for binding on 16007 at standard assay conditions or 
because 16007 virions more frequently sample conformations exposing 16007. The 
results from these studies suggest that DENV1 strain 16007 samples different or a 
broader range of conformations or samples conformations at a different frequency than 
DENV1 strain WP at steady-state, standard assay conditions; however, WP may sample 
alternate conformations that expose the E111 epitope following exposure to increased 
temperature and time. 
 
The difference in the neutralization potency of E111 against 16007 and WP was mapped 
to a single amino acid difference between these strains (K. Dowd and T. Pierson, 
unpublished data). When E protein residue 204 was mutated in WP from a K to an R, WP 
variant K204R demonstrated greatly enhanced sensitivity to neutralization by E111, 
similar to the level of sensitivity displayed by 16007. When the reciprocal mutation was 
introduced into 16007, 16007 variant R204K was significantly more resistant to E111, 
similar to levels observed for WT WP. Notably, residue 204 is located in E-DII outside of 
the E111 epitope in DIII. These data suggest that residue 204 may modulate the structural 
conformations sampled by WP and 16007. Notably, with the exception of strain 16007, 





The residues identified in Chapter 4 as a focus of the type-specific neutralizing antibody 
response to DENV1 vaccination based on the WP strain (residues E126 and E157) are 
highly conserved among DENV1 viruses (as assessed from over 1300 sequences 
available for analysis) (332). Despite the conservation of E126 and E157, strain-
dependent differences in structural dynamics could impact the exposure of epitopes that 
include these residues. Additionally, it is unknown what additional residues make up the 
epitope(s) containing E126 and E157, and whether they are conserved between DENV1 
strains. In this study, we investigated neutralization of heterologous DENV1 strains by 
sera from recipients of the NIH, WP-derived, DENV1 monovalent vaccine (14). We 
sought to determine whether the type-specific antibody specificities in polyclonal sera 
that mediate neutralization of WP are important in neutralization of heterologous DENV1 
strains. We characterized the effect of mutations E126K/E157K on heterologous DENV1 
strains, and observed strain-dependent differences in their impact on sensitivity to 
DENV1 sera that are mediated by differences in virion structural dynamics. This study 
provides insight into strain-dependent differences in recognition by polyclonal antibodies 
and highlights the complexities involved in understanding the contribution of individual 
residues to antibody recognition. 
 
5.2 Materials and Methods 
5.2.1 Cell lines 
HEK-293T cells and Raji-DCSIGNR cells were maintained at 37°C and 7% CO2. HEK-




containing Glutamax (Invitrogen, Carlsbad, CA), supplemented with 7.5% fetal bovine 
serum (FBS) (HyClone, Logan, UT) and 100 U/ml penicillin-streptomycin (PS) 
(Invitrogen, Carlsbad, CA). Raji-DCSIGNR cells were passaged in RPMI-1640 medium 
containing Glutamax (Invitrogen, Carlsbad, CA), supplemented with 7.5% FBS and 100 
U/ml PS.  
 
5.2.2 DENV immune sera 
Sera from recipients of phase I studies of candidate DENV1 or DENV2 monovalent 
vaccines were obtained for study. Pooled serum samples were from two (DENV1) or 
three (DENV2) vaccine recipients collected 2-3 years post-vaccination. The individual 
serum samples from 22 recipients of a DENV1 vaccine were collected on day 222 post-
vaccination (310). 
 
5.2.3 Ethics Statement 
Clinical studies were conducted at the Center for Immunization at the Johns Hopkins 
Bloomberg School of Public Health under an investigational new drug application 
reviewed by the United States Food and Drug Administration. The clinical protocol and 
consent form were reviewed and approved by the NIAID Regulatory Compliance and 
Human Subjects Protection Branch, the NIAID Data Safety Monitoring Board, the 
Western Institutional Review Board, and the Johns Hopkins University Institutional 
Biosafety Committee (ClinicalTrials.gov identifiers; NCT00473135, NCT00920517). 




Code of Federal Regulations (21 CFR 50) and International Conference on 
Harmonisation guidelines for Good Clinical Practice (ICH E6). 
 
5.2.4 Plasmids 
Plasmids encoding a WNV sub-genomic replicon and the structural genes of DENV1 
genotype 4 strain Western Pacific-74 (WP), DENV1 genotype 2 strain 16007, and 
DENV2 strain New Guinea C (NGC) have been described previously (34, 138, 226, 259-
261). For the construction of a plasmid encoding the structural genes of DENV1 
genotype 1 strain TVP2130, the structural genes were isolated from virus received from 
Dr. Michael Diamond (Washington University School of Medicine, St. Louis, Missouri) 
(47) through reverse transcription polymerase chain reaction (RT-PCR). The structural 
genes were cloned into the expression vector pcDNA6.2 (Invitrogen, Carlsbad, CA) and 
its sequence matched the CprME protein sequence of GenBank entry BAN63086.1. 
CprME variants were produced by site-directed mutagenesis using the Quikchange 
Mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions. 
All plasmids used in this study were propagated in Stbl2 bacteria grown at 30°C 
(Invitrogen, Carlsbad, CA). 
 
5.2.5 RVP production 
DENV RVPs were produced by complementation of a WNV replicon with plasmids 
encoding the structural genes of DENV as described previously (138, 259, 261). Briefly, 




replicon and DENV CprME in a 1:3 ratio by mass, using Lipofectamine LTX or 
Lipofectamine 3000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer’s 
instructions. RVPs were produced at 30°C in the presence of a low-glucose formulation 
of DMEM containing 25 mM HEPES (Invitrogen, Carlsbad, CA), 7% FBS, and 100 
U/ml PS. RVP samples were collected at 72, 96, 120, or 144 hours post-transfection, 
filtered using a 0.22μm syringe filter, and stored at -80°C. The infectious titer of RVPs 
was determined using Raji cells that express the flavivirus attachment factor DCSIGNR 
as described previously (130, 259). Following infection of Raji-DCISIGNR cells with 
serial dilutions of RVP samples, cells were incubated at 37C°C for two days and scored 
for infection as a function of GFP expression by flow cytometry. 
 
5.2.6 Neutralization assays 
DENV RVP stocks were diluted and incubated with serial dilutions of mAb or serum for 
one hour at room temperature prior to the addition of Raji-DCSIGNR cells, unless 
specified otherwise. Infections were carried out at 37°C for 48 hours and infectivity was 
scored as the fraction of GFP-expressing cells determined using flow cytometry. 
Antibody-dose response curves were analyzed using non-linear regression analysis (with 
a variable slope) (GraphPad Software, San Diego, CA). Data are expressed as the 






5.2.7 Statistical analysis 
Statistical analyses were performed using Prism software version 6.0f for Mac OS X 
(GraphPad). Log EC50 or Log NT50 values were compared using Student’s t-test when 
comparing two samples. For comparisons of more than two samples, Log NT50 values 
were compared by one-way ANOVA followed by Tukey’s multiple comparisons test.  
5.3 Results  
5.3.1 Characterization of RVPs encoding the structural genes of additional DENV1 
strains. 
The DENV1 component of the NIH DENV vaccine candidate is derived from DENV1 
strain WP (genotype 4) (14). We previously used RVPs of DENV1 strain WP to 
investigate the specificities of antibodies elicited by this vaccine (261). To investigate the 
specificities involved in polyclonal antibody recognition of other DENV1 strains, we 
selected two additional strains from heterologous genotypes for study: strain 16007 
(genotype 2) and strain TVP2130 (genotype 1). The E protein of strain 16007 differs 
from that of WP by 13 amino acids (2.6% variation), while the E protein of strain 
TVP2130 differs from that of WP by 11 amino acids (2.2% variation) (Figure 5.1). Of 
note, residue 204, which was shown to mediate the differences in structural dynamics 
between strains WP and 16007 (K. Dowd and T. Pierson, unpublished data), is conserved 
between strains WP and TVP2130.  
 
Following production of RVPs encoding the structural genes of DENV1 strains 16007 





Figure 5.1 Differences in E protein sequence between DENV1 strains WP, 16007, and TVP2130. (A) 
Amino acids in the E protein of 16007 and TVP2130 that are different from the WP residue are highlighted 
in grey. Residue location within the E protein ectodomain (DI, DII, and DIII) or within the stem or 
transmembrane (TM) is indicated on the top line. (B and C) Amino acid differences between the E proteins 
of (B) strains WP and 16007 or (C) strains WP and TVP2130 are highlighted in dark grey on the crystal 
structure of the ectodomain of the E protein. Additionally, residue E126 is highlighted in cyan and residue 
E157 is highlighted in green. The E protein domains are colored in red (DI), yellow (DII), and blue (DIII).   
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 E103. mAb E103 is a DENV1-type-specific antibody that binds a DIII epitope and has 
previously been shown, like E111, to neutralize strain 16007 more potently than strain 
WP (47). Likewise, we observed enhanced neutralization of strain 16007 (Log EC50 -
11.45 M) compared to strain WP (Log EC50 -10.19 M; p<0.0001) (Figure 5.2A). Strain 
TVP2130 was also neutralized more potently than strain WP (Log EC50 -10.95, 
p=0.0002), though not as potently as 16007 (p<0.0001). This is in contrast to mAb E111, 
which had decreased inhibitory activity against TVP2130 relative to WP (172). 
 
 We additionally tested the DENV1 strains for their sensitivity to neutralization by serum 
samples pooled from recipients of NIH DENV1 or DENV2 monovalent vaccine 
candidates (317, 318). For these experiments, we employed the pooled DENV serum 
samples previously used in Chapter 4 (Figures 4.2 and 4.4). Notably, though antibodies 
in these sera were raised against strain WP, strain 16007 was significantly more sensitive 
to neutralization by the pooled DENV1 sera compared to strain WP (3.1-fold difference, 
p=0.0001) (Figure 5.2B). In contrast, there was no significant difference in neutralization 
sensitivity between strains WP and TVP2130 (p=0.79). When the cross-reactive 
antibodies in DENV2 pooled sera were tested for an ability to neutralize the three 
DENV1 strains, no significant difference in the mean NT50 values was observed (p>0.75 
for WP vs. 16007 and for WP vs. TVP2130 comparisons) (Figure 5.2C). These data 
suggest that strain-dependent differences in structural dynamics may enhance the 
sensitivity of strain 16007 to neutralization by mAb E103 and DENV1 polyclonal sera in 
addition to mAb E111, but not to cross-reactive DENV2 sera. In contrast, while strain 





Figure 5.2 Neutralization sensitivity of DENV1 strains to polyclonal sera and monoclonal antibodies. 
(A) DENV1 strains were tested for their neutralization sensitivity to mAb E103. Mean EC50 values are 
shown for independent experiments for 16007 (n=4), WP (n=10) and TVP2130 (n=6). (B and C) DENV1 
strains 16007, WP, and TVP2130 were tested for neutralization sensitivity to pooled serum samples 
collected from two and three recipients of the DENV1 and DENV2 monovalent vaccines, respectively. (B) 
The mean neutralization titers of the DENV1 sera are shown from independent experiments for strains 
16007 (n=7), WP (n=5), and TVP2130 (n=7). (C) The mean neutralization titers of the DENV2 sera shown 
from independent experiments for 16007 (n=3), WP (n=11) and TVP2130 (n=4). For all panels, error bars 
















































level of sensitivity observed for strain 16007. Furthermore, strain TVP2130 did not 
display enhanced sensitivity to the DENV1 pooled sera.  
 
5.3.2 Differential neutralization of DENV1 strains by sera from DENV1 vaccine 
recipients.  
In order to further assess whether DENV1 sera raised against strain WP differentially 
neutralize heterologous DENV1 strains, we performed a screen using individual serum 
samples from recipients of the NIH DENV1 monovalent vaccine candidate. These serum 
samples were used previously in experiments described in Chapter 4 (Figure 4.10). For 
this screen, we employed sera collected on day 222 post-vaccination; 22 serum samples 
at this time point were available. DENV1 strains WP, 16007, and TVP2130 were tested 
for their sensitivity to neutralization by each of the 22 DENV1 serum samples. While the 
overall mean neutralization titers of the panel of sera were not significantly different 
against strain 16007 compared to strain WP (p=0.22) (Figure 5.3A), comparisons of 
individual neutralization titers revealed distinct patterns of neutralization. Serum samples 
from subjects 35 and 38 had decreased potency against strain 16007 (2.1-fold and 9-fold, 
respectively), whereas seven serum samples (32% of samples) had >2-fold increased 
potency against strain 16007 (Figure 5.3B). The remaining 13 serum samples (59%) 
neutralized strains 16007 and WP with NT50 values that differed by less than two-fold. 
The enhanced neutralization potency of almost one third of the sera against strain 16007 
relative to the strain that elicited the response may reflect antigenic differences arising 





Figure 5.3 Differences in neutralization potency of DENV1 sera against strains 16007, TVP2130, and 
WP. (A) Mean neutralization titers for 22 serum samples obtained 222 days following monovalent DENV1 
WP vaccination against DENV1 strains WP, 16007, and TVP2130. Error bars represent one standard 
deviation of the mean. ****p<0.0001; ns, p=0.22. (B) Fold difference in neutralization titer between strain 
WP and either strain 16007 (orange) or strain TVP2130 (green) obtained from pairwise experiments for 
each of the 22 serum samples. Values greater than 1 indicate increased neutralization sensitivity compared 
to strain WP while those less than 1 indicate decreased neutralization sensitivity. Mean NT50 values from 
1-3 experiments for each serum sample are shown; error bars represent standard error of the mean. 







































































In contrast to the results obtained for strain 16007, the mean neutralization titers against 
strain TVP2130 were 5.3-fold lower than those against strain WP (p<0.0001) (Figure 
5.3A). Furthermore, comparisons of individual neutralization titers reveal that 18 serum 
samples (82%) had >2-fold decrease in potency against strain TVP2130 compared to 
strain WP, while the remaining 4 serum samples (from subjects 41, 43, 45, and 55) 
neutralized strains WP and TVP2130 equivalently. These data indicate that DENV1 sera 
obtained following monovalent vaccination with strain WP display strain-dependent 
differences in neutralization potency.  
 
5.3.3 Characterization of E126K/E157K variants of DENV1 strains 16007 and 
TVP2130.  
As mentioned, residues E126 and E157, which were determined to be the focus of 
neutralizing antibodies against strain WP following monovalent DENV1 vaccination, are 
conserved among DENV1 strains. To test whether these residues are also important for 
the neutralization sensitivity of heterologous DENV1 strains to DENV1 WP vaccine sera, 
we produced E126K/E157K variants for DENV1 strains 16007 and TVP2130. To ensure 
that the E126K/E157K mutations introduced into strains 16007 and TVP2130 did not 
result in changes in overall antigenicity of the E protein, variants were first characterized 
for sensitivity to neutralization by control antibodies that target epitopes outside those 
defined by E126/E157, and that were previously used to characterize the WP variant 
(Figure 4.7 and 4.8). First, the variants were tested for sensitivity to neutralization by 
pooled DENV2 sera. Mean NT50 values against 16007 variant E126K/E157K were not 




(Figure 5.4A). Likewise, we did not observe a large difference in NT50 values against 
TVP2130 variant E126K/E157K compared to WT TVP2130 (2-fold; p=0.053; n=3) 
(Figure 5.4B). Second, the variants were tested for sensitivity to neutralization by mAb 
E60, a cross-reactive, maturation state-sensitive antibody that binds the DII fusion loop. 
The EC50 values of E60 against 16007 variant E126K/E157K were not significantly 
different from those against WT 16007 (<2-fold different; p=0.61; n=3) (Figure 5.4C). 
Likewise, EC50 values of E60 against TVP2130 variant E126K/E157K and WT TVP230 
were not significantly different (<2-fold different; p=0.38; n=4) (Figure 5.4D). Third, the 
variants were tested for their sensitivity to neutralization by DIII-binding mAb E103. 
EC50 values of E103 against 16007 variant E126K/E157K and WT 16007 were not 
significantly different (<2-fold different; p=0.07; n=3) (Figure 5.4E). Likewise, EC50 
values of E103 against TVP2130 variant E126K/E157K and WT TVP2130 were not 
significantly different (<2-fold different; p=0.76; n=4) (Figure 5.4F). 
 
Altogether, these results indicate that mutations E126K/E157K, when introduced into 
DENV1 strains 16007 or TVP2130, did not alter overall antigenicity of the E protein. 
5.3.4 Effect of mutations E126K/E157K on neutralization of DENV1 strains 16007 
and TVP2130 by DENV1 sera. 
We next assessed the 16007 and TVP2130 E126K/E157K variants for sensitivity to 
neutralization by DENV1 sera. Although the WP E126K/E157K variant was previously 
shown to have significantly reduced sensitivity to the pooled DENV1 sera relative to WT 
WP (9.8-fold change, Figure 4.6C and D), the 16007 E126K/E157K variant displayed 





Figure 5.4 Characterization of E126K/E157K variants of DENV1 strains 16007 and TVP2130. 
E126K/E157K variants of DENV1 strains 16007 and TP2130 were compared to the WT virus for 
sensitivity to neutralization by DENV2 pooled sera, mAb E60, and mAb E103. Within each panel, 
representative dose response curves are shown of the left; error bars represent the range of duplicate 
infections. Mean NT50 or EC50 values from independent experiments are shown on the right; error bars 
represent the standard error of the mean; ns, p>0.05. (A and B) Neutralization potency of DENV2 pooled 
sera against (A) 16007 E126K/E57K and (B) TVP2130 E126K/E157K. (C and D) Neutralization potency 
of mAb E60 against (C) 16007 E126K/E57K and (D) TVP2130 E126K/E157K. (E and F) Neutralization 





















































































































































































































































































































fold change, p=0.10, n=4) (Figure 5.5A and B). In contrast, the TVP2130 E126K/E157K 
variant displayed significantly reduced neutralization sensitivity compared to WT 
TVP2130 (5.6-fold change, p=0.014, n=4) (Figure 5.5C and D).  
 
We next assessed neutralization of 16007 and TVP2130 E126K/E157K variants by 
individual DENV1 serum samples. For this screen, we chose a random subset (13 
samples) of the 22 individual serum samples studied in Figure 5.3. Each serum sample 
was measured for neutralization activity against the E126K/E157K variant of 16007 or 
TVP2130 in parallel with WT DENV1 strains WP, 16007, and TVP2130, and DENV2 
strain NGC. DENV2 neutralization titers were used as a reference to quantify the type-
specific component of the serum neutralizing activity. In Figure 5.6A, the fold 
differences in neutralization titer between DENV2 and each WT DENV1 strain are 
shown, indicating the extent of the type-specific neutralization of each serum sample 
against each DENV1 strain. Analysis of the majority of the DENV1 sera revealed 
significant type-specific patterns of neutralization against DENV1 strain WP, with an 
average 9.4-fold increase in titer against WP compared to DENV2 (Figure 5.6A). Of the 
13 samples tested, 10 had >6-fold increase in titer between WP and DENV2. The type-
specific titers against DENV1 strain 16007 were even more pronounced than those 
against WP, with an average 18.4-fold increase in titer relative to DENV2 (Figure 5.6A). 
As with WP, 10 of the samples neutralized 16007 with >6-fold greater potency compared 
to DENV2, with the remaining three samples displaying a 3- to 5-fold increase in 
potency. In contrast, the type-specific titers against DENV1 strain TVP2130 were much 





Figure 5.5 Effect of mutations E126K/E157K on the sensitivity of strains 16007 and TVP2130 to 
neutralization by DENV1 pooled sera. (A and B) WT 16007 and 16007 E126K/E157K were tested for 
sensitivity to neutralization by DENV1 pooled sera (from Figure 5.2B). (A) A representative dose-
response curve is shown. Error bars represent the range of duplicate infections. (B) Mean NT50 values are 
shown from 4 (WT 16007 or 16007 E126K/E157K) or 2 (DENV2) independent experiments; error bars 
represent the standard error of the mean; ns, p=0.10. (C and D) WT TVP2130 and TVP2130 
E126K/E157K were tested for neutralization sensitivity to DENV1 pooled sera. (A) A representative dose-
response curve is shown. Error bars represent the range of duplicate infections. (B) Mean NT50 values are 



























































































































Figure 5.6 Sensitivity of DENV1 E126K/E157K variants to neutralization by DENV1-immune serum 
samples. DENV1 16007 and TVP2130 E126K/E157K variants were tested in parallel with WT 16007, WT 
TVP2130, WT WP, and WT DENV2 for sensitivity to neutralization by 13 DENV1-immune serum 
samples. Data from Figure 4.10 for the WP E126K/E157K variant are included. (A) The fold difference in 
neutralization titer between each WT DENV1 strain and WT DENV2 is shown. Higher numbers indicate 
greater type-specific neutralization potency. (B) The fold difference in neutralization titer between each 
DENV1 E126K/E157K variant and WT DENV2 is shown. For both panels, red shading indicates a <3-fold 
difference, yellow shading a 3- to 6-fold difference, and green shading a >6-fold difference in titer. 
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32 9.4 22.1 2.7
33 3.9 3.8 1.6
35 13.1 15.8 3.8
38 12.8 5.2 3.5
41 3.7 3.1 2.9
43 8.5 11.8 4.2
44 12.1 13.5 5.5
45 13.0 96.6 16.3
46 10.9 10.6 1.4
50 11.9 16.3 4.6
51 3.5 5.0 2.9
53 10.5 18.5 3.1
55 8.5 16.4 7.0
mean 9.4 18.4 4.6
WT DENV1 strain              
/DENV2











32 1.4 15.3 1.0
33 1.6 3.3 0.9
35 2.9 6.9 2.0
38 4.5 6.0 3.1
41 1.4 2.3 0.7
43 1.7 10.9 1.4
44 2.9 8.8 2.0
45 5.3 80.2 9.3
46 0.5 2.0 0.5
50 0.9 7.5 1.5
51 1.6 4.1 1.7
53 1.6 11.8 1.7
55 0.7 5.3 1.6
mean 2.1 12.6 2.1
DENV1 E126K+E157 variant 
/DENV2




13 serum samples, only two had a >6-fold increase in titer against TVP2130 compared to 
DENV2, while six had between a 3- to 6-fold increase in titer, and five had <3-fold 
increase in titer.  
 
Figure 5.6B shows the extent of type-specific neutralization of each serum sample that 
was remained after introduction of the E126K/E157K mutations. In addition to the data 
obtained for E126K/E157K variants for strains 16007 and TVP2130, previously reported 
data for WP variant E126K/E157K (from Figure 4.10) are included for reference. As 
previously discussed, mutations E126K/E157K ablated the majority of the type-specific 
neutralization titers against DENV1 WP, such that the mean neutralization titers against 
this variant and DENV2 were within 2.1-fold. Of the 13 samples used in this study, 11 
neutralized the WP E126K/E157K variant and DENV2 with similar potency (<3-fold 
difference in titer), and the remaining two samples displayed <6-fold difference. For 
TVP2130, as for WP, the E126K/E157K mutations ablated the majority of the type-
specific neutralization titers, with an average 2.1-fold difference in neutralization titer 
between the TVP2130 variant and DENV2 (Figure 5.6B). Twelve of the 13 samples had 
<3-fold difference in titer between the variant and DENV2, while the remaining sample 
retained a 9-fold difference. In contrast, the 16007 E126K/E157K variant was still 
neutralized in a type-specific manner by the majority of sera: seven samples had >6-fold 
difference in titer against the 16007 variant compared to DENV2, while four had a 3- to 
6-fold difference, and only one sample had <3-fold difference (Figure 5.6B). These 
results indicate that, in the context of DENV1 strains WP and TVP2130, mutations 




elicited by a DENV1 vaccine. However, in the context of strain 16007, residues E126 and 
E157 do not play as large a role in polyclonal antibody recognition.  
 
5.3.5 Impact of E protein residue 204 on neutralization of 16007 by DENV1 sera. 
Although the antibodies in the DENV1 sera were raised against the WP strain, many of 
the serum samples more strongly neutralized DENV1 strain 16007. Our hypothesis is that 
differences in structural dynamics increase the exposure of epitopes on 16007 that are 
cryptic on WP. Because the amino acid difference at residue 204 has previously been 
shown to mediate differences in structural dynamics between the two strains, we 
investigated the ability of DENV1 sera to neutralize 16007 variant R204K. Sera from 
subjects 32, 33, and 51, which were each more potent against 16007 compared to WP 
(Figure 5.3), were tested for neutralization potency against 16007 R204K. All three sera 
displayed reduced activity against 16007 R204K relative to WT 16007, similar to levels 
observed for WP (Figure 5.7A-C).  
 
These results indicate that differences in structural dynamics mediated by residue 204 
may contribute to the enhanced neutralization of 16007 by DENV1 sera. Alternatively, if 
residue 204 is part of epitopes recognized by antibodies in sera, the R204K mutation may 
be directly impacting antibody binding (antibody affinity). To test this hypothesis, we 
introduced a non-chemically conservative substitution at residue 204 in 16007: a change 
in charge from a basic R to an acidic D residue. Unlike R204K, the R204D substitution 
did not alter the sensitivity of 16007 to neutralization by mAb E111 (Figure 5.7D and 




Figure 5.7 Impact of E protein residue 204 on neutralization of strain 16007 by DENV1 sera. (A-C) 
Sera from three DENV1 vaccine recipients were analyzed for their neutralization potencies against DENV1 
strains WP, 16007, and 16007 variant R204K. Shown are the dose response curves for sera from (A) 
subject 32, (B) subject 33, and (C) subject 51. (D and E) mAb E111 was assessed for its neutralization 
potency against 16007 variants R204D and R204K, in addition to WT DENV1 strains 16007 and WP. (D) 
Shown is a representative dose response curve. Error bars represent the range of duplicate infections. (E) 
Shown are the mean E111 EC50 values from four (16007 WT, 16007 R204K, and WP) or two (16007 
R204D) independent experiments. Error bars represent the standard error of the mean. (F and G) 16007 
variants R204D and R204K and WT DENV1 strains 16007 and WP were assessed for their sensitivity to 
neutralization by four serum samples from DENV1 vaccine recipients. (F) Summary of the NT50 values 
for sera from all four subjects. (G) Dose response curves for all four serum samples. Error bars represent 
the range of duplicate infections.   





































































































































































































































previously shown to neutralize 16007 more potently than WP. If the chemically 
conservative R204K mutation affects the potency of DENV1 sera by directly disrupting 
antibody interactions, then the R204D mutation would likely also impact antibody 
recognition by the DENV1 sera. However, 16007 variant R204D and WT 16007 
displayed similar sensitivities to DENV1 sera (Figure 5.7F and G), in contrast to the 
reduced sensitivity of 16007 R204K relative to WT 16007. These results suggest that the 
amino acid difference at residue 204 between strains WP and 16007 may modulate virion 
structural dynamics and alter the exposure of epitopes targeted by neutralizing antibodies 
in polyclonal sera. 
 
5.4 Discussion 
A DENV vaccine needs to elicit an immune response that is protective against the diverse 
strains that circulate for each serotype. Thus, it is important to characterize the antibody 
response elicited by a vaccine against heterologous strains. We previously studied the 
antibody response elicited by the DENV1 component of the NIH tetravalent vaccine 
candidate against DENV1 strain WP, the strain used in the vaccine. We determined that 
type-specific neutralizing antibodies in the polyclonal sera targeted epitopes containing 
residues E126 and E157 on DII and DI, respectively (261). While residues E126 and 
E157 are largely conserved among DENV1 strains, other residues important for 
recognition of epitopes comprised of these residues are not known. Notably, a DENV1 
WP variant containing a mutation at residue K203 had reduced sensitivity to 
neutralization by several serum samples from DENV1 vaccine recipients, indicating that 




However, analysis of the ~1300 available DENV1 sequences revealed that <1% of 
DENV1 sequences contain a K at residue 203, while >99% contain an E. A K to E 
charge-change is likely to affect antibody recognition of epitopes in which residue 203 
contributes to antibody binding. Therefore, if residue 203 is important for antibody 
recognition by antibodies elicited by the DENV1 WP vaccine, these antibodies may have 
reduced potency against 99% of heterologous DENV1 strains.  
 
We investigated antibodies elicited against the DENV1 WP vaccine for potency against 
heterologous DENV1 strains 16007 and TVP2130. The greatly reduced potency of 
vaccine sera against TVP2130 compared to WP (Figure 5.3) may be due to amino acid 
variation within functionally important epitopes. While residues E126 and E157 are 
conserved, TVP2130 differs from WP at residue 203 and the neighboring residue, 202 
(Figure 5.1). Of note, the substitutions at 202 and 203 are both charge changes. Residues 
202 and 203 are located proximal to residue E126 (~10-15 Å away), and could 
potentially be part of E126-containing epitopes. TVP2130 differs at additional residues 
proximal to residue E126 (residues 225 and 88 are 9 and 19 Å away, respectively) and at 
a residue proximal to E157 (residue 155 is 3 Å away). Unlike the charge changes at 202 
and 203, the substitutions at 88, 225, and 155 are chemically conservative; however, 
conservative differences still have the potential affect the potency of antibodies. Thus, the 
observation that the majority of the DENV1 sera had decreased potency against TVP2130 
may be due to the amino acid variation at residues 88, 155, 202, 203, and/or 225. 
Characterization of TVP2130 variants encoding mutations at these positions would be 




residues in the E126- and E157-containing epitopes that are important for antibody 
recognition.  
 
Despite the decreased neutralization activity against WT TVP2130, some type-specific 
neutralization against this strain was observed: the majority of DENV1 serum samples 
neutralized WT TVP2130 >3-fold more potently than DENV2 (Figure 5.6A). Notably, 
the majority of the type-specific activity against TVP2130 was ablated by mutations 
E126K/E157K, similar to observations for strain WP (Figure 5.6B). Therefore, while 
type-specific antibodies in the DENV1 sera are less potent against TVP2130, the 
specificities that mediate type-specific neutralization appear to be conserved between WP 
and TVP2130. 
 
In contrast to the reduced potency of the DENV1 sera against strain TVP2130, the 
majority of DENV1 sera neutralized strain 16007 with similar or greater potency than 
strain WP. That antibodies raised against strain WP were more potent against 
heterologous strain 16007 was surprising. Additionally, there is greater variation between 
the E proteins of strains 16007 and WP than between those of strains TVP2130 and WP 
(Figure 5.1). Like strain TVP2130, strain 16007 differs from WP at residues 202, 203, 
and 88 (proximal to E126). Strain 16007 additionally differs at residue 180 (20 Å from 
residue 157) and residue 204 (12 Å from E126). Despite the amino acid variation 
proximal to residue E126 and E157, only two serum samples had reduced potency against 
strain 16007 compared to strain WP (Figure 5.3). Furthermore, when mutations 




the type-specific neutralization potency: the fold difference in titer relative to DENV2 
was 18.4 for WT 16007 and 12.4 for 16007 E126K/E157K. The neutralization potency of 
the majority of serum samples was >3-fold greater against 16007 E126K/E157K than 
against DENV2. These results suggest that, while mutations E126K/E157K moderately 
impact neutralization of strain 16007, additional antibody specificities must be 
contributing to the type-specific neutralization of strain 16007.  
 
The distinct antibody specificities that mediate neutralization of strains 16007 and WP 
may be due to the different structural dynamics of this strain. What these additional 
antibody specificities are is not known at this time. Determining the additional epitopes 
that are recognized on strain 16007 would require a screen of new 16007 variants, similar 
to the screen performed on strain WP. Additionally, the neutralization titers of nAbs that 
bind epitopes outside of DIII should be compared for WT 16007, 16007 R204K and other 
DENV1 strains.  
 
That over half of the DENV1 serum samples displayed similar potencies against strains 
16007 and WP (Figure 5.3) could suggest that the epitopes targeted by neutralizing 
antibodies in these samples are largely unaffected by differences in virion structural 
dynamics. If that were the case, then the same antibody specificities should be mediating 
neutralization of both strains. However, our data indicate that different antibody 
specificities mediate neutralization of strain 16007. An alternative explanation is that an 
increase in neutralization potency against strain 16007 due to structural dynamics may be 




antibody footprints. As discussed above, strain 16007 varies from strain WP at several 
residues in DI and DII that are proximal to E126 and E157 (residues 88, 180, 202, 203). 
In this “sum of opposing forces” model, due to the polyclonal nature of sera, distinct 
antibody specificities could be mediating neutralization of strains 16007 and WP, yet 
result in similar potencies against the two strains. Characterization of additional 16007 
variants could help elucidate what antibody specificities are involved in polyclonal 
antibody neutralization of strain 16007.  
 
The three DENV1 strains studied within each displayed unique patterns of sensitivity to 
neutralization by DENV1 polyclonal sera obtained following monoclonal vaccination 
with a DENV1 candidate vaccine based on the WP strain. Whether this vaccine would be 
capable of mediating protection against distinct DENV1 strains is not known. 
Additionally, it would be interesting to compare antibody specificities elicited against 
different DENV1 strains. Do the distinct structural dynamics displayed by strain 16007 
make it a better or worse immunogen? Would a DENV1 strain containing the more 
conserved glutamic acid at residue 203 offer broader neutralization potency against 
diverse DENV1 strains? The results of this study highlight the complexities involved in 






Chapter 6: Discussion4 
 
 
The humoral response to viral infection has the potential to yield large numbers of B cells 
that produce antibodies with varied specificities, affinity for viral antigens, and functional 
properties. Considerable insight into how antibodies protect against infection, via direct 
neutralization of viral infection or antibody effector function, has come from studies of 
mAbs (57, 104, 130, 140, 141, 145, 172, 342-344). However, how antibodies function in 
concert as part of a polyclonal response is not well understood, nor is the breadth of the 
functionally significant components. For example, it is unclear why infection or 
vaccination may elicit antibodies that display neutralizing activity in vitro but contribute 
only modestly, if at all, to protection in the host. Two complementary approaches have 
been used successfully in an attempt to deconstruct the functional complexity of the 
polyclonal response. First, large panels of human mAbs have been created for many 
pathogens, allowing a detailed analysis in vitro and in vivo of the individual components 
of an antibody response. For flaviviruses, these approaches have yielded insights into 
how antibodies engage the many surfaces of the virion (50, 59, 60). Second, several 
studies, including the study outlined in this dissertation, have used novel molecular and 
biochemical approaches to identify epitopes recognized by nAbs within sera (54, 197, 
261, 324-326, 345). Below, the findings from these two approaches are integrated and 
discussed in the context of the current understanding of the antibody response to 
                                                
4 Adapted in part from: VanBlargan LA, Goo L, Pierson TC. Deconstructing the Antiviral Neutralizing 





flaviviruses and more broadly to other viruses, and how these findings can contribute to 
vaccine design.  
 
6.1 Neutralizing Antibodies Are A Rare Component Of The Humoral Response 
Against Infection  
Virus-specific human mAbs are identified by screening B cells for their ability to produce 
antibodies with desired functional properties. In many instances, candidate B cells, either 
MBCs or LLPCs, are screened for the ability to bind recombinant viral proteins (50, 346-
348), virus-like particles (349, 350), or intact virions (57, 351) and then immortalized. 
Use of relatively high throughput neutralization assays has allowed functional screens to 
identify B cell clones that produce potent nAbs directly (352). The significant complexity 
of the antigenic surface of viruses suggests that the characteristics of the antigen used for 
screening, as well as the screening strategy will almost certainly impact the repertoire of 
mAbs identified (59).   
 
In most instances, analyses of human anti-flavivirus mAbs suggest that antibodies with 
limited neutralizing activity comprise a large fraction of the virus-specific antibody 
response (50, 57, 59, 60, 353). For example, less than 5% of the antibodies isolated from 
flavivirus-infected or vaccinated humans displayed potent neutralizing activity (EC50 
<0.5 mg/ml) (169, 301). A significant portion (~45-60%) of the total E protein-specific 
response appears to be directed against the highly conserved fusion loop in domain II 
(DII-FL) (169, 319, 343). Antibodies that target prM are also frequently isolated (50, 59, 




weakly inhibit infection (50, 168, 169, 171, 301, 343, 353). These antibodies bind 
epitopes that are either poorly accessible for antibody recognition (54) or are not present 
on virions with a stoichiometry sufficient to exceed the threshold requirements for 
neutralization (32, 54, 130). Similarly, although broad and potent nAbs against HIV-1 
have been isolated from infected individuals (354), these nAbs represent a rare 
component of the overall humoral immune response. For example, a screen of 25 million 
peripheral blood mononuclear cells (PBMCs) from an individual whose serum displayed 
cross-reactivity against diverse HIV-1 strains identified only 3 somatically-related mAbs 
targeting the CD4 binding site that recapitulated the broad and potent neutralizing activity 
of the polyclonal serum (347).  
 
Part of the challenge of eliciting effective nAbs against structurally complex viruses may 
be a requirement to engage a specific subset of the B cell repertoire. In support of this 
hypothesis, broadly neutralizing antibodies (bnAbs) against the HIV-1 CD4 binding site 
isolated from multiple donors appear to arise from a common, limited subset of germline 
genes that remarkably converge in sequence and structure during the affinity maturation 
process (348, 355-358). Antibodies elicited following acute DENV infection or influenza 
vaccination among unrelated individuals also display convergent sequence signatures 
(359, 360).  
 
6.2 Neutralizing Antibodies Target A Limited Number Of Specificities  
To complement studies of human mAb specificities, several groups have developed 




the nAb response to flavivirus infection or vaccination. One approach is to compare the 
neutralizing activity of sera pre-incubated with soluble recombinant antigens representing 
various E protein domains to that of untreated sera. Such serum depletion studies have 
shown that DIII is not a major target of human nAbs following vaccination or natural 
infection with DENV (326), WNV (319), YFV (361), and TBEV (362), despite being the 
target of very potent murine neutralizing mAbs (47-49, 52, 56, 363, 364). These findings 
are supported by genetic approaches demonstrating that mutations in DIII epitopes do not 
result in a significant reduction in the neutralization potency of flavivirus immune sera 
from humans (319, 326). Most of the neutralizing activity of serum following YFV or 
DENV infection or vaccination is not affected by depletion by soluble E protein, 
suggesting that quaternary epitopes may be important targets for nAbs (326, 361), as 
discussed more below. In general, most studies characterizing anti-flavivirus nAb 
specificities in human polyclonal sera have largely ruled out the importance of particular 
epitopes, such as those in DIII and DII-FL (50, 60, 319, 326, 327).  
 
The study outlined in this dissertation has identified residues on the E protein targeted by 
nAbs in polyclonal DENV-reactive sera. Epitopes targeted by nAbs elicited by a 
monovalent DENV1 vaccine candidate were investigated by creating and characterizing a 
comprehensive panel of DENV1 variants in which surface-accessible residues of the E 
protein were replaced by corresponding sequences of a DENV2 strain (261). This panel 
was screened to identify mutations that reduced sensitivity to neutralization by DENV1, 
but not DENV2, immune sera. This strategy identified two residues in DI and DII that 




4.10) (261). The idea that the anti-flavivirus immune response is focused on just a few 
specificities aligns with data from recent studies on HIV-1, in which most analyses of 
polyclonal sera with broadly neutralizing activity suggest that just one to two specificities 
can recapitulate the breadth and potency of the overall sera neutralizing activity (329, 
365-367). Follow-up studies with multiple DENV serotypes will be needed to explore the 
fine specificity of type-specific nAbs.  
 
Characterizing the kinetics and components of polyclonal sera over time may help define 
pathways to highly functional antibodies targeting critical epitopes. For example, there is 
increasing evidence that the continuous cycle of HIV-1 neutralization and escape from 
early strain-specific antibodies in sera often indirectly results in the exposure of epitopes 
that gradually lead to the induction of bnAbs during chronic infection (331, 368-371). It 
is possible that initial binding of antibodies to a particular epitope affects subsequent 
binding of other serum antibodies on the virion surface (149). This phenomenon may 
play a role in shaping the antibody repertoire that mediates potent neutralization. 
Additionally, the presence of antibodies bound to an antigen may affect subsequent 
antibody specificities that are elicited through epitope shielding. For example, distinct 
antibody specificities were elicited in mice following immunization with a TBEV E 
protein when the E proteins used for immunization were bound by antibody compared to 
unbound E proteins (362). It would be interesting to extend this finding to immunization 
with whole virus, as well as to secondary DENV infections, when presumably the virus is 





6.3 Epitope Specificities Of Neutralizing Antibodies Inform Vaccine Design  
Identifying the epitope specificities of protective antibodies to gain insight into strategies 
to elicit them via vaccination is the focus of rational vaccine design efforts for many 
viruses (372-375). Because of the complex and dense arrangement of flavivirus E 
proteins on the virion surface, not all epitopes are equally accessible to antibodies (296). 
Antibodies that bind poorly accessible or cryptic epitopes are characterized by greater 
occupancy requirements for neutralization and are capable of enhancing the infection of 
FcR-expressing cells at high concentrations (50, 60, 130, 376). This enhancement of 
infection has been linked mechanistically to more severe clinical outcomes of DENV 
infection (12, 84). Thus, a flavivirus vaccine that elicits antibodies targeting accessible 
epitopes may be more optimal for providing protection. However, as discussed below, 
depending on the biology and pathogenesis of the virus, accessible epitopes may not 
always be ideal targets for the most protective antibodies. The characterization of large 
panels of potently neutralizing mAbs has greatly improved our understanding of the 
molecular basis of antibody recognition and neutralization and has the potential to inform 
vaccine design.  
 
6.3.1 Accessible epitopes: easy targets.  
Neutralization of flaviviruses is governed by a requirement for “multiple hits” whereby 
antibodies that target highly accessible epitopes can achieve neutralization at a lower 
occupancy compared to those targeting poorly exposed epitopes (130). In support of this, 
many of the most potent mAbs characterized to date bind highly accessible epitopes on 




discontinuous epitope in the lateral ridge of DIII (DIII-LR), neutralizes at picomolar 
concentrations in vitro (364), and prevents WNV-induced mortality in animals when 
given as a single dose after infection (364, 378). Cryo-electron microscopy studies 
demonstrate that E16 can bind its epitope on 120 out of 180 E proteins on the mature 
virion (144), allowing antibody binding to exceed the stoichiometric threshold for 
neutralization at low occupancy (130) (Figure 6.1A).  
 
In the study outlined in this dissertation, residues selected for mutagenesis were surface 
exposed on the structure of the mature virus. Thus, this strategy biased the screen to 
identifying residues in epitopes that are (at least partly) accessible. That this strategy was 
successful in identifying the principal targets of the type-specific neutralizing antibody 
response to DENV1 vaccination suggests that functionally significant antibodies elicited 
by the vaccine likely target epitopes with exposed residues.  
 
6.3.2 Cryptic epitopes: dynamic targets.  
In contrast to highly potent antibodies that target accessible epitopes, antibodies that bind 
hidden epitopes often mediate neutralization only at very high concentrations. However, 
viral factors that modulate epitope accessibility, such as the efficiency of virion 
maturation and viral “breathing”, contribute significantly to the ability of antibodies to 
recognize cryptic epitopes (32, 34, 138, 172). For example, DENV1 mAb E111 
recognizes an epitope on DIII predicted to be inaccessible on the mature virion (Figure 
6.1B), and is weakly neutralizing against the majority of DENV1 strains tested under 





Figure 6.1 Examples of epitopes targeted by anti-flavivirus monoclonal antibodies. Epitopes of 
selected mAbs are shown in green on the E protein dimer (PDB: 1OAN) (top panel) or in red on the mature 
virion (PDB: 4CCT) (bottom panel). (A) Monoclonal antibody E16 targets the DIII lateral ridge, a highly 
accessible epitope on the virion surface (144). (B) Monoclonal antibody E111 recognizes a cryptic epitope 
on DIII that is poorly accessible on the mature virion (172). This mAb may rely on virus “breathing” for 
epitope accessibility. (C) Monoclonal antibody EDE2-B7, targets a quaternary epitope that spans adjacent 




neutralization of DENV1 following increases in the time and temperature at which virus-
antibody immune complexes are incubated, which allows for virus “breathing” to expose 
the E111 epitope for antibody binding (172). Two additional DENV-specific mAbs that 
similarly recognize cryptic epitopes are the murine mAbs 4E11 (379) and 1A1D-2 (51). 
Both mAbs target an epitope centered on the A-strand of DIII-LR that is not predicted to 
be accessible for antibody recognition on mature virions (173), as the fusion loop is 
inserted into the hydrophobic pocket near the DIII A-strand on the partner E protein in 
the dimer, thus theoretically blocking the binding site of 4E11 and 1A1D-2 (334). 
Presumably, these mAbs bind and stabilize the A-strand epitope as it becomes transiently 
available on the “breathing” virion. In support of this, 1A1D-2 has been shown to bind to 
the DENV virion at 37°C, but not at room temperature, suggesting that temperature-
dependent increases in the mobility of E proteins on the virion surface promote 
accessibility of the A-strand epitope (173).  
 
Virion maturation state also plays a role in modulating the exposure of cryptic epitopes. 
For example, the WNV-specific murine mAb E53 binds an epitope that includes residues 
in the DII-FL and adjacent BC loop (171). This mAb has almost no neutralizing activity 
against fully mature WNV virions, but displays increased neutralization potency against 
virions that retain uncleaved prM on the surface (32). Cryo-electron microscopy studies 
revealed that the E53 Fab binds preferentially to spikes on immature flavivirus virions, 
providing a structural basis for the maturation-state dependence of E53 neutralizing 





Although the presence of a stoichiometric threshold of neutralization suggests that highly 
accessible epitopes are ideal targets for potent nAbs, for viruses with extensive genetic 
and antigenic heterogeneity such as HIV and influenza, epitopes that are highly exposed 
are often highly variable. Potent nAbs can develop against hypervariable loops that shield 
more conserved regions in the HIV envelope (166), but these antibodies tend to be highly 
strain-specific, and rapidly select for escape variants (reviewed in (380)). An enormous 
challenge in developing an effective vaccine against rapidly evolving viruses is the 
requirement to elicit potent antibodies against conserved sites that are often occluded and 
are thus poorly immunogenic (reviewed in (381)). Nonetheless, a number of conserved 
vulnerable sites on the HIV envelope that are recognized by broad and potent nAbs have 
been identified. These include the CD4 binding site (347, 355, 382), glycan-dependent 
epitopes in V1/V2 (352) and V3 (383) of gp120, the membrane proximal external region 
(MPER) (384) of gp41, and most recently, epitopes spanning both gp120 and gp41 
subunits (385-388).   
 
In contrast to the apparent accessibility of DIII-LR epitopes that elicit strongly 
neutralizing, virus-specific antibodies against flaviviruses, epitopes that induce broad and 
potent nAbs against HIV are often buried under a dense shield of glycans or are deeply 
recessed on the native trimer (389, 390). However, the remarkable potency of some 
bnAbs against HIV suggests that such epitopes are exposed frequently enough to allow 
antibody binding to exceed the neutralization threshold. Alternatively, such potency may 
reflect the unusual characteristics displayed by most HIV bnAbs identified to date, such 




glycans (reviewed in (354)). For example, the broadly neutralizing mAb VRC01 encodes 
41 VH gene alterations and 25 Vκ gene alterations from the germline sequence (390). A 
separate study found that only one percent of VH genes from IgG memory and GC B cells 
had greater than 40 mutations (94). Further identification and characterization of 
additional HIV antibodies and epitopes will help clarify whether these unusual 
characteristics are required to achieve broad and potent neutralization (179, 391). 
 
6.3.3 Quaternary epitopes: complex targets.  
Many nAbs target complex, conformational, surface-accessible epitopes that are only 
optimally exposed on an intact virion, but not on soluble envelope proteins. For example, 
a recent analysis of 145 human mAbs isolated from seven DENV infected patients found 
that over 40% of the mAbs were only reactive against whole virions, and not against 
recombinant E protein (191, 392). Most of these virion-specific antibodies target an 
epitope that overlaps the DII-FL epitope and bridges the E dimer interface (E-dimer 
dependent epitope; EDE) (Figure 6.1C) (191, 392). Importantly, these mAbs display 
very potent neutralization across all four DENV serotypes (191, 392). The specificity of 
the EDE mAbs differs from that of most of the other potently neutralizing, anti-flavivirus 
mAbs targeting quaternary epitopes across adjacent E protein dimers. These latter 
antibodies often recognize epitopes that overlap the DI/DII hinge, and include the human 
anti-WNV mAb CR4354 (145), and anti-DENV mAbs 5J7, 1F4 (57), and HM14c10 (58). 
The prevalence of nAbs targeting complex epitopes is not limited to those against 
flaviviruses, as many of the most potent HIV-1 bnAbs have been found to recognize 




of antibodies targeting these complex epitopes is due to their ability to bind to sites that 
are only exposed on the most functional configuration of the viral envelope. 
 
The mutagenesis strategy outlined in Chapter 4 identified individual residues, not entire 
epitopes, that were targeted by the polyclonal antibody response. Because other residues 
contributing to epitopes containing residues 126 and 157 were not defined, it is not 
known whether residues 126 and 157 are part of quaternary epitopes. Notably, however, 
many of the human mAbs isolated to date that bind nearby epitopes in DI and/or DII 
recognize quaternary epitopes (57, 58, 145, 342). A type-specific, potently neutralizing 
human mAb, 1F4, was recently characterized that recognizes an epitope on DI of 
DENV1, including residue E157 identified in our study (393). While the epitope of 1F4 is 
entirely contained within one E monomer, 1F4 binds whole virions but not recombinant E 
protein, suggesting its epitope is quaternary structure-dependent (57, 393).  
 
The discovery of potent nAbs that recognize quaternary epitopes exposed only on the 
virion surface has important implications for the identification and analysis of functional 
components of the polyclonal antibody response against viruses. In addition to the 
apparent rarity of B cells that contribute to the neutralizing component of the antibody 
response, one possible explanation for the discrepancy between dominant binding versus 
neutralizing epitope specificities is that many antiviral nAbs target quaternary epitopes 
that are only optimally exposed on the virion surface, and are thus not faithfully 





6.4 Future directions 
In this dissertation, the human, type-specific, neutralizing antibody response to a live 
attenuated, DENV1 monovalent vaccine was investigated. The mutagenesis strategy 
developed within to identify functionally important targets of the antibody response could 
be applied to future studies to investigate and compare antibody responses to different 
types of DENV1 vaccination and infection events. It would be of interest to compare the 
antibody specificities elicited by the NIH DENV1 vaccine studied within to infections 
with heterologous DENV1 strains. It would also be of interest to compare antibody 
responses to different types of immunogens, such as viruses that differ with respect to 
maturation state or conformational dynamics (such as DENV1 strains WP and 16007). 
Additionally, antibody responses to different types of vaccines could be compared, such 
as live-attenuated vaccines versus inactivated virus, recombinant E protein, or DNA 
vaccines.  
 
Similar systems could be easily developed to study the other DENV serotypes and used 
to identify whether neutralizing antibodies against heterologous serotypes targets similar 
regions of the E protein. These systems could also be used to investigate how the 
antibody response is skewed following tetravalent vaccination or following sequential 
exposures such as after secondary infections or sequential heterotypic vaccination (394).  
 
In addition to the neutralizing abilities of DENV Abs, effector functions such as ADCC 
may be involved in DENV protection or pathogenesis (302-304). Antibody specificities 




for studying the neutralizing potency of antibodies is not able to measure antibody 
effector functions, current ADCC assays may be modified using aspects of our system for 
investigating ADCC-mediating Ab specificities. 
 
6.5 Concluding Remarks 
Much of our mechanistic understanding of virus/antibody/host interactions has been 
gleaned from the study of mAbs. However, a polyclonal antibody response against a 
particular pathogen may contain a diverse array of antibodies that can differ drastically 
with regards to epitope specificity, neutralizing potency, effector function, and breadth of 
recognition (narrow type-specificity vs. broad cross-reactivity). Within this diverse 
repertoire of a polyclonal response, the fraction of antibodies that contribute substantially 
to protection may be small. 
 
As different viruses employ multiple distinct antibody evasion strategies, the epitope 
diversity required for optimal protection may vary among viruses. Because of the 
potential for non- or weakly neutralizing antibodies to contribute to pathogenesis of 
DENV infection (81), eliciting antibodies against accessible epitopes (including 
quaternary determinants) that allow high occupancy binding at low concentrations may 
be ideal (130). In contrast, for viruses that exhibit more extensive antigenic variability, 
such as HIV-1 and influenza, an effective vaccine may need to elicit potent nAbs against 
hidden epitopes that are conserved across multiple variants. The ability of these viruses to 
rapidly escape from immune pressure may suggest a role for nAbs with multiple 




antibody specificity is likely to be effective in providing protection against diverse HIV-1 
variants, but combining antibodies that target distinct neutralization epitopes increases 
overall neutralization coverage (383, 395-400). Currently, it is unclear whether eliciting 
broad and potent nAbs against multiple epitopes via vaccination is feasible, although 
there is evidence that such nAbs can develop within a single individual during HIV-1 
natural infection (329, 401, 402). 
 
Identifying the specificities of nAbs elicited following vaccination or natural infection 
may guide immunogen design to more effectively engage the subset of naïve B-cell 
receptors that lead to broadly protective functional responses. This information is 
especially relevant given recent advances in deep sequencing technology coupled with 
proteomic analysis of antigen-specific IgG that allow the isolation and characterization of 
functionally relevant antibodies from polyclonal sera (403, 404). Thus, it has become 
possible to enrich for epitope-specific nAbs and characterize their ontogeny to inform 
vaccine design (348, 355)). Finally, there is growing evidence that functionally relevant 
epitopes grafted onto molecular scaffolds can serve as promising immunogens (374, 
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